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The dopamine transporter (DAT) is an integral membrane protein that mediates 
the reuptake of synaptic dopamine and thus regulates the spatio-temporal dynamics of 
dopaminergic neurotransmission. DAT is also the target of powerful addictive 
psychostimulants, including cocaine and methamphetamine that resulted in dysregulation 
of dopaminergic signaling. Complex control of DAT is exerted by various regulatory 
processes, including posttranslational modifications. We previously found that DAT is 
palmitoylated via the addition of a 16-carbon palmitic acid moiety to Cys 580. 
Pharmacological and mutagenic studies determined that depalmitoylation conditions led 
to reductions in Vmax and transporter levels, suggesting palmitoylation controls one or 
more functions of DAT. Palmitoylation is a dynamic and reversible process catalyzed by 
palmitoyl acyltransferases (PATs) and depalmitoylation is catalyzed by palmitoyl-protein 
thioesterases (PPTs). PAT enzymes have been further classified as DHHC enzymes based 
on a conserved cysteine rich domain and the active site sequence Asp-His-His-Cys. 
Currently, 23 PAT enzymes have been identified in the human genome with some 
associated with dopaminergic diseases such as schizophrenia; however, the enzymes that 
act on DAT are unknown. Therefore, we hypothesized that specific PAT enzymes will 
drive DAT palmitoylation, controlling expression, DA transport, and membrane lateral 
mobility of the transporter. To address this question, we co-expressed a specific subset of 
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neuronally-expressed PATs individually with DAT and assessed DAT palmitoylation, 
total and surface expression, transport activity, and lateral membrane mobility. 
Additional studies were also conducted to investigate psychostimulant regulation of DAT 
palmitoylation.  
Palmitoylation assessed by acyl-biotin exchange revealed that the neuronal PATs, 
DHHC2, DHHC3, DHHC8, DHHC15, and DHHC17 increased DAT palmitoylation at 
Cys580, while several others had no effect, indicating a level of substrate specificity for 
actions against DAT. We observed a correlation between increased DAT palmitoylation 
and increased total DAT expression, consistent with a role for palmitoylation opposing 
DAT degradation. DAT palmitoylation also led to enhanced DA uptake with no effect on 
surface levels, suggesting that palmitoylation also increases transport capacity via an 
alteration of DAT transport kinetics. Our results also indicated that DAT palmitoylation 
increased the time for recovery after photobleaching, suggesting that increased 
palmitoylation decreases the membrane lateral mobility of the transporter. Lastly, we 
observed treatment with methamphetamine but not cocaine resulted in decreased DAT 
palmitoylation in both heterologous cells and in animal models, suggesting that DAT 
palmitoylation is regulated by psychostimulants. Palmitoylation thus plays an important 
role in both short- and long-term regulation of DAT by controlling multiple functions. 
Therefore, this modification could potentially affect neurotransmitter clearance in 






The Synaptic Neurotransmission of Dopamine 
 
 The brain is responsible for physiological and psychological processes of the 
entire human body. It consists of billions of neurons which communicate by signals from 
one neuron to another through the release of neurotransmitters. One particular 
neurotransmitter we are interested in is dopamine (DA). DA was discovered in 1957, by 
Dr. Arvid Carlsson, when he investigated dopamine in the brains of reserpinized animals 
treated with L-DOPA  (1). Initially, DA was thought to only be the precursor to another 
neurotransmitter norepinephrine; however, Carlsson discovered that DA was important 
for physiological function (1–3). DA is important for several physiological roles 
including movement, reward, and mood. DA like other catecholamines (epinephrine and 
norepinephrine) is derived from tyrosine which is abundantly found in dietary proteins. 
Initially, tyrosine is transported into the dopaminergic neuron by amino acid transporters. 
Once tyrosine enters the neuron, it is converted to L-3, 4-dihydroxyphenylalanine (L-
DOPA). This process is catalyzed by cytosolic tyrosine hydroxylase (TH) and the 
cofactors oxygen, iron, and tetrahydrobiopterin hydroxylates tyrosine. This step in DA 
synthesis is the rate-limiting step (4). L-DOPA is then decarboxylated to produce DA by 
aromatic L-amino acid decarboxylase (AADC). Because DA is the starting compound to  
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generate other neurotransmitters, DA synthesis regulates the synthesis of norepinephrine 
and epinephrine, the other two catecholamines. 
 Once DA has been synthesized, the neurotransmitter is transported from the 
cytoplasm into synaptic vesicles via the vesicular monoamine transporter 2 (VMAT2), 
where it is stored until release. The concentration of DA in the vesicles is 0.1M, which is 
10-1000 times higher than the level in the cytosol (4). Neurotransmitter release of DA is 
initiated by an action potential that triggers the opening of voltage-gated Ca2+ channels 
resulting in a rapid rise in intracellular Ca2+. The transient increase in Ca2+ stimulates the 
fusion of the synaptic vesicles with the plasma membrane of the presynaptic neuron 
(synaptic vesicular exocytosis) and the release of the stored DA into the synaptic cleft 
(5). Once DA is released into the synaptic space it binds to specific receptors found on 
both the pre and postsynaptic neurons. Neurotransmission is terminated when the excess 
DA is removed from the synapses by diffusion or reuptake. A small amount of DA is 
metabolized by catechol-O-methyltransferace (COMT) and by monoamine oxidase 
(MAO) in which homovanillic acid is formed (HVA) (4). However, the primary way DA 
is removed from the synapse is by the reuptake of DA back into the presynaptic neuron 
through the action of the dopamine transporter (DAT). DA can then be repackaged into 
vesicles, awaiting another round of vesicular release. This process is depicted in the 
schematic diagram in Figure 1.  
Dopamine Pathways and the Hypothesis of Reward 
Much of what is known about dopaminergic pathways and behavior comes from 




Figure 1: Schematic diagram of dopaminergic neurotransmission. Dopamine (gold 
circles) is synthetize and packed into synaptic vesicles (light blue) by the vesicular 
monoamine transporter 2 (VMAT2) (pink rods). Upon an action potential, synaptic 
vesicles dock at the plasma membrane of the presynaptic neuron and releases dopamine 
into the synaptic cleft. Dopamine then binds the dopamine receptors (green cylinders) on 
the postsynaptic neuron, resulting in dopaminergic neurotransmission (yellow lightning 
bolt). Dopamine can also bind to dopamine autoreceptors on the presynaptic neuron 
(green cylinders). Dopaminergic neurotransmission is terminated when dopamine is  
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Figure 1 continued: removed from the synapse by the dopamine transporter (purple 
trapezoids). Once dopamine is taken up into the presynaptic neuron, it is repackaged into 









neurons (6–8). From these studies and others, the major dopamine-mediate pathways 
were discovered. It was determined that there were four major trajectories of midbrain 
dopamine neurons, each forming the major dopaminergic pathways (Figure 2). The 
mesolimbic pathway projects from the ventral tegmental area (VTA) to the limbic system 
in the nucleus accumbens. These neurons are involved in reward and pleasure pathways 
and have been associated with diseases such as schizophrenia, attention deficit 
hyperactivity disorder (ADHD), and addiction. The nigrostriatal pathway projects from 
the substantia nigra to the striatum in the basal ganglia. These neurons are important for 
movement and motor control and have been associated with Parkinson’s disease. The 
tuberinfundibular pathway extends from the hypothalamus to the posterior pituitary. 
These neurons are important for the inhibition of prolactin secretion, and have been 
associated with hyperprolactinaemia disorder. Finally, the mesocortical pathway projects 
from the VTA to the frontal cortex. These neurons are important for motivation, emotion, 
and attention, therefore associated disorders include schizophrenia, ADHD, and 
addiction.  
Initial electrical stimulation experiments on rats in the 1950s revealed that the 
brain has specialized centers that control reward functions (9). Additional studies 
determined that the dopaminergic system was sensitive to electrical self-stimulation in 
the midbrain from dopaminergic neurons found in the limbic regions. Studies have shown 
synaptic DA is not only increased by natural rewards such as food, water, and sex, but 
also by drugs such as cocaine (10, 11). Furthermore, studies have found cocaine self-




Figure 2: Dopaminergic pathways in the brain. Dopamine neurons projecting from the 
VTA to the nucleus accumbens form the mesolimbic pathway (red). Dopamine neurons 
projecting from the VTA to the frontal cortex form the mesocortical pathway (blue). 
Dopamine neurons projecting from the substania nigra to the striatum form the nigrostrial 
pathway (purple). The tuberinfundibular pathway (green) extends from the hypothalamus 
to the posterior pituitary. Image modified from Okinawa Institute of Science and 




thus it is thought that the mesolimbocortical pathways are important for mediating 
reinforcement processes of cocaine (13, 14).Together, these studies support the dopamine 
hypothesis of reward, that suggest drugs of abuse are rewarding due to the increase in DA 
in the mesolimbic system (13).  
To further study the dopamine hypothesis, investigators observed a  DAT 
knockout (KO) mouse  (15). In this model, disruption of the mouse DAT gene resulted in 
spontaneous hyperlocomotion, signifying the importance of DAT in the dopaminergic 
system (15).  In DAT KO mice, DA remained in the extracellular space 100 times longer 
than wild-type (WT) animals, suggesting clearance by diffusion. Investigators concluded 
that in the WT animals, DA was cleared faster due to the presence of DAT, suggesting 
DAT is the key factor in controlling synaptic dopamine levels and ending 
neurotransmission. From these studies it was also demonstrated that DAT was the target 
of these psychostimulant drugs including cocaine and amphetamines (15).  
However, other studies suggest more than one system may be important for 
reward. Rocha et al. found DAT KO mice self-administered cocaine (16), while others 
have found DAT KO mice displayed cocaine-conditioned place preference (17). 
Together, these studies suggested the possibility of other systems such as the serotonergic 
system that may be involved in the rewarding effects of cocaine. To further study this 
concept, serotonin (SERT) KO mice were generated to evaluate the serotonergic system 
in reward pathways. SERT KO mice also displayed cocaine-conditioned place preference 
(17), however, the combined DAT/SERT KO mice did not. In contrast, norepinephrine 
(NET)/SERT KO mice and NET/DAT KO mice still displayed cocaine-conditioned place 
preference (18), strengthening the argument that SERT may also be involved in the 
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reward pathways. The DAT KO mice were shown to have many adaptive changes 
including reduction in DA, tyrosine hydroxylase, and D1 and D2 dopamine receptor 
levels (15), suggesting adaptive changes may alter the normal reward pathways. 
To overcome the adaptive changes observed with the DAT KO mouse, a DAT 
knock-in mouse line carrying a cocaine-insensitive but functional DAT was created (19). 
A triple mutations made in TMD 2 resulted in a 69-fold reduction in cocaine inhibition, 
while nearly 50% of DAT was retained compared to WT DAT (19). Furthermore, the 
cocaine insensitive knock-in mice displayed abolished cocaine self-administration and 
cocaine reward as measured by conditioned place preference (20). These results support 
the dopamine hypothesis, suggesting that DAT is necessary for cocaine reward in mice 
with a fully functional DAT (20).  
The Dopamine Transporter 
The solute carrier 6 (SLC6) are a family of secondary active co-transporters that 
use extracellular sodium and chloride as a driving force for substrate translocation (21). 
This family is divided into four subclasses based on sequence similarity and substrate 
specificity (22). The subfamilies include the neurotransmitter transporters (NTT), the 
amino acid transporters, creatine transporters, and osmolyte transporters. Specifically, the 
NTT family includes three γ-aminobutyric acid (GABA) transporters (GAT), two glycine 
transporters (GLY) and the monoamines, SERT, NET, and DAT.  
DAT is a plasma membrane protein expressed in dopaminergic neurons and is 
essential for regulating dopaminergic neurotransmission. Molecular cloning of DAT has 
been done in several species including human, rat, mouse, monkey, Drosophila 
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melanogaster, and Caenorhabditis elegans. From these studies the primary sequence of 
human (h) and rat (r) DAT is predicted to be 620 and 619 amino acids, respectively, with 
hDAT containing an extra glycine at position 199 (23). The predicted structure in 
mammalian DAT includes 12 transmembrane spanning domains, intracellular termini, 
and a large extracellular loop (EL) between TMD 3 and 4 that contains four glycosylation 
sites (23–26) (Figure 3). Additionally, four zinc coordinating residues have been 
identified that are important for stabilizing the outward facing conformation of DAT, 
acting as a DA uptake inhibitor (27, 28). The zinc coordinating residues found in both 
EL2 and EL4, are H193 (EL2), D206 (EL2), H375 (EL4), and E396 (EL4) on hDAT (27, 
28). 
DAT is also modified by many posttranslational modification found throughout 
the protein. The posttranslational modifications include phosphorylation and 
ubiquitylation on the N-terminal tail, glycosylation on EL2, and palmitoylation on the C 
terminus (discussed in future section) (Figure 3). Together these posttranslational 
modifications affect the regulation, function, and structure of DAT.  
Ubiquitylation is a posttranslational modification in which an ubiquitin group is 
added to a lysine residue. Mass spectrometry analyses of DAT indicated constitutive 
ubiquitylation of DAT, with an increase in DAT ubiquitylation upon PKC activation. 
(29). Ubiquitylation of other transmembrane proteins was found to be important as a 
sorting signal for endocytosis and lysosomal degradation; therefore, experiments were 
conducted to determine if this was also true for DAT (30).  A triple mutation of Lys19, 




Figure 3: Schematic diagram of the rat dopamine transporter. The structure contains 12 
transmembrane domains with N- and C-termini intracellularly oriented. The blue residues 
represent the transmembrane domains. The large extracellular loop (EL) 2 contains the 
four glycosylation sites and the N-terminal tail contains two ubiquitylation sites, depicted 
in yellow. The zinc coordination sites found in EL2 and EL4 are represented by red. The 
PKC dependent serine phosphorylation sites and the threonine proline-directed 
phosphorylation site are depicted in blue, with the proline represented by a green residue. 
The blue cysteine residue on the C-terminus denotes the palmitoylation site on rDAT.
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internalization, suggesting the ubiquitin moieties conjugated to DAT are important for 
interactions with the endocytic machinery (30).  
DAT is also heavily glycosylated protein, with the sugars attached to asparagine 
residues in EL2 (31). Research has shown glycosylation of DAT is important for 
trafficking and targeting DAT to the cell (32, 33).  Furthermore, proper DAT folding was 
found to be facilitated by a disulfide bond in EL2 between cysteines 180 and 189 (34).  
This bond was found to be important for proper function of DAT (34).  
Studies have also shown that DAT is a phosphoprotein (35–37). This 
posttranslational modification on DAT affects DAT function and is regulated by protein 
kinases, suggesting another mechanism for temporal and spatial control of synaptic 
transmitter levels in dopaminergic signaling. Through phosphoamino acid and protease-
based peptide mapping analysis, the direct region of DAT phosphorylation in rat brain 
tissue was determined (38). Results identified one or more serines on the N terminal tail 
to be the major sites of both basal and stimulated phosphorylation (38). Additional 
studies identified the cluster of serines present within the first 21 N-terminal residues to 
be the site where the majority of basal, PKC-induced, and amphetamine-induced 
phosphorylation occurs (38–40). Through mutagenic studies, serine 7 was identified as 
the major site of PKC dependent phosphorylation in both rat striatal DAT and 
heterologous cells expressing rat and human DAT (41). Interestingly, a mutation at serine 
7 resulted in decreased binding affinity for a cocaine analog, further suggesting 
phosphorylation at serine 7 is important for regulation transporter conformation (41).  
An additional phosphorylation site on DAT was also determined to be important 
for DAT function (37). Studies identified DAT to be phosphorylated at residue Thr53 in 
12 
 
rat and mouse striatum, as well as in heterologous cells (42). Mutagenic studies at 
position 53 resulted in reduced DA transporter Vmax, suggesting the importance of this 
residue in transporter kinetics (42). This site is different from the PKC phosphorylation 
site since the Thr53 residue is followed by a proline, making it specific for proline-
directed kinases, such as extracellular signal regulated kinase (ERK). Phosphorylation of 
proline-directed sites are characterized by alterations in protein structure due to the 
protein being regulated by cis-trans isomerization of the phosphoacceptor-prolyl peptide 
bond (43), suggesting Thr53 may play a role in the transporter function by affecting the 
conformation of the protein.  
The Structure and Transport Mechanism 
 Prior to the first high resolution X-ray crystal structure of the bacterial homolog 
of the SLC6 transporters, most of the structural understanding was based on observations 
and mutagenesis studies. However, that changed in 2005, when the leucine transporter 
(LeuT) from the thermophile bacterium Aquifex aeolicus was crystalized with the 
substrate leucine and two sodium ions bound (44). For the first time, this prokaryotic 
homolog gave insight into the transporters topology and secondary structure. The 
crystalized structure confirmed many predictions by revealing 12 TMD connected by 
short intracellular and extracellular loops, in addition to intracellular N and C termini. 
The overall LeuT structure is asymmetric with two similar structural motifs arranged by a 
pseudosymmetric inverted repeat architecture. The 5 + 5 + 2 architecture shows TMDs 1-
5 and 6-10 to form helical bundles that are antiparallel, resulting in a pseudo two fold 
axis symmetry. The TMDs pack together in a helix bundle to form two distinct regions of 
the transporter, the interior core, and the outer region. The inner core is formed by 
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TMD1, TMD3, TMD6, and TMD8, together these TMDs form the central substrate 
binding site (S1) as well as the Na+ binding sites. Overall, LeuT and SLC6 transporters 
share 20-25% sequence identity. However, the central core that is important for transport 
and substrate binding share a high sequence identity of about 55-67% (44, 45). 
Furthermore, 7 of the 11 residues in LeuT that have direct interactions with the substrate 
are conserved in all nine mammalian neurotransmitter transporters, suggesting the S1 site 
is structurally conserved between LeuT and SLC6 transporters (21). This finding is 
supported by experimental evidence also identifying the S1 residues (45–48).  
Although the LeuT structure is the basis for the SLC6 family of transporters it is 
important to note there are several differences between the prokaryotic and eukaryotic 
SLC6 transporters (44). The eukaryotic transporter has much longer intracellular N-and 
C-termini; a longer EL2 loop which contains a disulfide bond and glycosylation sites; and 
finally several posttranslational modifications that affect the regulation and function of 
the transporter. Prior to the LeuT crystal structure it was suggested from sequence 
analysis and biochemical approaches that the monoamine family included these important 
posttranslational modifications (33, 49). Although models of eukaryotic transporters 
based on LeuT provided insight into substrate binding, there are still many questions 
regarding the structure and function. In 2013, the Gouaux lab crystalized the Drosophila 
melanogaster dopamine transporter (dDAT) (50) (Figure 4A). The structure of dDAT 
was crystallized at a 3.0 A resolution bound to the tricyclic antidepressant nortriptyline. 
The dDAT has over 50% sequence homology with the mammalian transporters DAT, 




Figure 4. Crystal structure of the dopamine transporter. (A) x-ray crystal structure of the 
Drosophila melanogaster dopamine transporter (dDAT) in complex with the TCA 
nortriptyline. The structure also shows a cholesterol molecule wedged into a groove formed 
by TMD1, TMD5, and TMD7. (B) Locations of the open extracellular gate (red box), 
closed intracellular gate (blue box), and C-terminal latch (green box). Image modified from 
A. Penmastal, K.H. Wang, and E. Gouaux. 2013. X-ray structure of the dopamine 




was additional information provided by this structure. The dDAT structure determined 
that a cholesterol molecule was wedged in a groove formed by TMD1, TMD5, and 
TMD7, likely important for stabilizing the outward-open conformation (51, 52).The 
structure also revealed two attributes on the C-terminus. First the crystal structure 
revealed a kink in TMD12 halfway across the membrane bilayer at Pro572 that causes the 
intracellular portion of the helix to turn away from the transporter. The structure also 
revealed a latch-like C-terminal helix thought to be important for interactions with the 
cytoplasmic face of the transporter. The C-terminal helix was also found to interact with 
IL1, which interacts with TMD1a (Figure 4B). The close proximal interaction with the 
cytoplasmic gate suggests the C-terminal helix may be important for modulating 
transport activity (50). Together, the LeuT and dDAT crystal structures provided 
important information about the structures and mechanism of SLC6 transporters that was 
previously unknown. 
The process through which DAT transports substrate from the outside of the cell 
to the inside of the cell is known as the alternating access mechanism. The alternating 
access mechanism was first coined in 1966 by Dr. Oleg Jardetzky (53). This term was 
used to describe the conformational changes transporters use to alternate through when 
transporting substrate from the extracellular space into the cytoplasm. Now with a more 
complex understanding, it is widely accepted that membrane proteins, including SLC6 
proteins, transport their substrate through a series of conformational changes via the 
alternative access mechanism (21, 54) (Figure 5). The transition of these conformations 





Figure 5: The alternating access mechanism model of the dopamine transporter. A 
schematic representation of the conformations of DAT important for translocation of 
substrate from the extracellular space to the cytoplasm. (A) The transporter in an outward 
facing conformation allowing substrate to bind. The transporter is facing the extracellular 
space with the extracellular gate open and the intracellular gate closed. (B) The transporter 
is an outward occluded (C) or inward occluded configuration in which ions and substrate 
are in there appropriate binding sites, both the extracellular and intracellular gates are 
closed. (D) Inward facing conformation. The extracellular gate is closed while the 
intracellular gate opens allowing substrate and ions to be released into the cytoplasm of the 
cell. Once the substrate is released, the transporter will return to the outward facing  
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Figure 5 continued: conformation awaiting the next round of translocation. Image modified 
from Kristensen AS, Andersen J, Jorgensen TN, Sorensen L, Eriksen J, Loland CJ, 
Stromgaard K, and Gether U. 2011. SLC6 neurotransmitter transporters: structure, 




DAT cycles through outward and inward facing conformations that allow for 
binding of substrates and release into the cytoplasm. Initially, when DAT is in the 
outward open conformation, the extracellular gate is open allowing substrate to bind. At 
the same time, the intracellular gate is closed, sealing off the cytoplasmic side from the 
aqueous extracellular environment (Figure 5A). Once the substrate is bound, the 
transporter transitions into an occluded state in which both the extracellular and 
intracellular gates are closed (Figure 5B and C). In a similar manner, the intracellular gate 
is opened while the extracellular gate is closed thus releasing the substrate into the cell 
(Figure 5D). Once the substrate has been released the transporter returns to the lowest 
energy conformation, outward facing, waiting for the next substrate to bind. The gating 
residues responsible for the transition of conformations are based on the LeuT structure 
(44). The extracellular gate is formed by the ionic interaction of Arg85 and Asp477. 
Additionally, Tyr156 and Phe320 form aromatic lids that act as a secondary external gate, 
preventing access to the central substrate binding site. The intracellular gate is formed by 
the ionic interaction of Arg60, Ser334, Tyr335, and Asp436. Additionally, Trp63 
stabilizes the intracellular halves of TMDs 1 and 6. There have been several proposed 
models for the translocation of substrate in the transporter core during the outward to 
inward transition. One model suggests the unwound region in the middle of TMD1 and 
TMD6 acts as a flexible hinge that can move the intracellular halves independently 
during a conformational outward to inward transition (21, 44, 55, 56). Another proposed 
model suggests TMD1 and TMD6, along with TMD2 and TMD7, form a rigid body that 
rocks back and forth allowing the transition between outward and inward facing 
conformations (21, 54). The conformation of the transporter is important for kinetics 
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regulation and functionality. Changes in conformation can result in reverse translocation 
of substrate (efflux), which requires binding and outward translocation of intracellular 
DA (57, 58).  
Regulation of DAT by Psychostimulants- Blockers and Substrates 
DAT is the target of many clinically used drugs, such as bupropion (Wellbutrin®,  
an antidepressant), methylphenidate (Ritalin®, ADHD medication), and mazindol  
(Mazindor®, an appetite suppressant) (21, 59). As well, DAT is also the main site of 
action for powerful addictive psychostimulants including cocaine and methamphetamine 
(METH). These drugs work by disrupting normal dopaminergic neurotransmission by 
either blocking DAT or increasing DA efflux. Both conditions lead to prolonged 
dopaminergic signaling resulting in the euphoric feeling associated with drug addiction 
(60). Neurochemical imaging studies have shown chronic use of cocaine or METH can 
lead to long-term impacts on DAT levels by mechanisms that are not fully understood 
(61, 62). In addition to the direct effects on DA transports, multiple studies have shown 
that DAT activity is regulated by blockers and substrates after pretreatment followed by 
washout, indicating drugs of abuse can affect dopaminergic neurotransmission even after 
the removal of the drugs.  
The two classifications of drugs that act on DAT are substrates and blockers. 
Drugs like cocaine act as blockers by binding to DAT and inhibiting the reuptake of DA 
from the synapse, increasing synaptic DA levels. Cocaine has been shown to effect DAT 
regulation in postmortem samples of human cocaine addicts (63), suggesting chronic 
abuse of cocaine can cause long term effects in humans. In contrast to blockers, AMPH 
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and METH act as DAT substrates, competing with endogenous DA for transport and 
inducing DA efflux through transporter reversal  (59, 64–67).METH and AMPH have 
been shown to have pronounced alterations on DAT trafficking and DA uptake levels 
(59, 64–68). These effects on transport and surface expression have been shown to be 
blocked by cocaine, indicating these substrates are activity transported into the cell by 
DAT (59, 64) Studies show short time exposure (less than 1 minute) to AMPH results in 
DAT recruitment to the plasma membrane and an increase in transport (69–71). It is 
thought this rapid recruitment of DAT is important for clearance of extracellular DA 
induced by the drug (69, 71). In contrast longer exposure to METH and AMPH have 
resulted in DAT downregulation and endocytosis of DAT (39, 71–73). Downregulation 
after longer substrate exposure times is thought to be a neuroprotective mechanism by 
limiting the cytosolic accumulation of DA and its neurotoxic metabolites. 
AMPH-stimulated downregulation is thought to occur by both kinetic and 
endocytotic downregulation mechanisms, because AMPH-induced downregulation has 
been found in the absence of endocytosis (72, 74). Research has shown that METH-and-
AMPH-induced DAT phosphorylation can be blocked by inhibition of PKC, 
demonstrating PKC is involved in the regulation of DAT by substrates (39, 75, 76). 
Likewise, METH and PKC induced DAT phosphorylation can be reduced by the 
truncation of the first 21 residues in DAT, suggesting METH and PKC-mediated 
phosphorylation occur in the same region of DAT. AMPH and METH have also been 
shown to stimulate DA efflux (59, 64–67) , however this mechanism is poorly 
understood. Additionally, AMPH stimulated efflux can be impaired when deletions of 
distal N terminal serines or disruption of the CaMKIIa binding domain occur (77, 78), 
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though it is not clear how the N-terminus and CaMKIIa operate together for AMPH 
induced efflux.  
DAT Protein-Protein Interactions 
It is well known that DAT is not an isolated protein, but rather a highly regulated 
multiprotein complex formed by protein-protein interactions (79) that regulate  
trafficking and function of DAT. Multiple proteins are known to bind and interact with 
both the N-and C-termini of the transporter (Figure 6). Regulatory partners discovered to 
interact with the N-terminus include Syntaxin 1A (Syn1A) and D2 receptors. Using a 
yeast two-hybrid system, Syn1A (80) was revealed to have novel interactions with DAT. 
Syn1A is a member of the soluble N-ethylmaleimide sensitive factor attachment protein 
receptor (SNARE) protein family and has been shown to mediate AMPH-induced DA 
efflux in murine synaptosomes and in C. elegans to regulate DAT1 ion channel activity 
(81, 82). Together, these studies have identified the Syn1A binding site on DAT to be on 
the N-terminus of DAT at residues 1-33. (81, 82). Additional studies aimed at 
understanding the regulation of Syn1A and DAT found that an overexpression of Syn1A 
reduces transport Vmax and affects surface expression (83). Furthermore, cleavage of 
Syn1A, with the protease Botulinum Neurotoxin C (BoNT/C) increases DA transport 
Vmax and reduced DAT phosphorylation, suggesting Syn1A interaction with DAT may 
affect regulatory mechanism important for DAT function (84). Another protein known to 
directly interact with DAT is the G-protein coupled receptor (GPCR) family member, 
dopamine receptor, D2. D2 receptors function as autoreceptors allowing an inhibitory 
feedback mechanism by altering DA synthesis, release, and reuptake in response to 
increasing levels of extracellular DA found in the synapse. D2 and DAT interactions 
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involve the N-terminus of DAT and the third intracellular loop of the D2 receptor (85). 
The physical interaction facilitates the  recruitment of DAT to the plasma membrane 
resulting in enhance DA uptake (85).  
Other DAT regulatory partners that interact with DAT near the C-terminus of the 
transporter include, protein interacting with kinase 1 (PICK1), Rin1 (Ras-like in 
neurons), flotillin 1 (Flot1),calcium-calmodulin-dependent protein kinase (CaMKIIa), 
Parkin, and α-synuclein (α-syn) (77, 86–91).  PICK1 is a PSD-95/Discs- larger/ZO-1 
(PDZ)-domain containing protein that is important for clustering receptors and ion 
channels (92). Interestingly, hDAT contains a PDZ binding sequence (LKV) at the end of 
the C-terminus. PICK1 was a candidate for a regulatory interaction of DAT based on a 
yeast two-hybrid screening (86). Originally, the interaction between PICK1 and  DAT 
was thought to be important for endoplasmic reticulum (ER) export of DAT. Initial 
studies, found the truncation of C terminal of DAT resulted in ER retention and impaired 
surface expression (86). However, it was later demonstrated that the PDZ-binding 
interactions of DAT was not necessary nor sufficient for DAT surface expression in 
heterologous cells (93). Additional in vivo studies determined DAT knock-in mice with 
disrupted PDZ-binding motifs had a dramatic loss of DAT expression in the striatum, 
suggesting PDZ domain interactions were critical for synaptic distribution of DAT in 
order to maintain DA homeostasis (94).  
Rin was identified by yeast two-hybrid screening to interact with DAT was (88). 
Previous studies determined residues 587-596 (FREKLAYA) encoded an endocytic 
regulatory domain that modulates both basal and PKC-enhanced DAT internalization 
rates; (87). Therefore, studies aimed at understanding where Rin binds were performed. It  
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Figure 6: DAT protein-protein interactions. The transporter is positioned in the membrane 
lipid bilayer with the N-and-C termini. The various binding partners of DAT are depicted 
based on where they bind or interact with DAT. Syntaxin 1A (Syn1A), dopamine 
autoreceptor2 (D2), protein interacting with kinase 1 (PICK1), Rin1 (Ras-like in neurons), 
flotillin 1 (Flot1), calcium-calmodulin-dependent protein kinase (CaMKIIa), Parkin, and 
α-synuclein (α-syn).  Modified image from Vaughan RA and Foster JD. Mechanisms of 
dopamine transporter regulation in normal and disease states 2013. Trends in 




was determined that Rin interacts with DAT at residues 587-590 on the C-terminus in a 
PKC-regulated manner, which is required for PKC-mediated DAT internalization (88).  
Flot1 also known as Reggie 2 is a membrane raft protein whose binding site on 
DAT is currently unknown (95). Flot1 is highly conserved and expressed in the nervous 
system and thought to be important for endocytosis (96). This protein associates with the 
membrane in a cholesterol-dependent manner, resulting in hetro-oligomers and 
microdomains in the plasma membrane (97).  Current, studies suggest Flot1 is required for 
PKC-triggered endocytosis of DAT (95). Furthermore, it was determined that DAT 
complexes with palmitoylated Flot1 in a PKC-dependent manner and a conserved serine 
residue of Flot1 is required for PKC-mediated internalization. It was also demonstrated 
that Flot1 is important to maintain DAT in membrane rafts, suggesting DAT membrane 
microdomain localization may be important for endocytosis of DAT; however unknown at 
this time (95).  
CaMKIIa binds to the distal C-terminus of DAT at residues 612-617 (77) and has 
been shown to play an important role in AMPH-mediated efflux of DA in heterologous 
cells and dopaminergic neurons. Fog et. al. demonstrated in vitro that CaMKIIa is 
responsible for phosphorylating the serines found on the distal N terminus (77). A mutation 
made on the C-terminus impaired CaMKIIa binding and AMPH-induced efflux. Thus 
suggesting CaMKIIa binding to DAT on the C-terminus facilitates phosphorylation of 
DAT on the N terminus.  
Parkin and α-syn are two proteins associated with Parkinson’s disease.  Initial 
studies determined that α-syn interacts with the carboxyl tail of hDAT, resulting in the 
formation of membrane clustering, thereby increasing DA uptake and DA induced 
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cellular apoptosis (98).This was proposed to be a possible mechanism for the degradation 
of dopaminergic nerve terminal is Parkinson’s disease (98). It was later determined that 
parkin, an E2-dependent E3 protein ubiquitin ligase, exerts protective effects against DA-
induced α-syn toxicity (90). This study established that parkin impairs the α-syn and 
DAT complex by interacting with the carboxyl tail of DAT and blocking α-syn induced 
enhancement of DAT surface expression and DA uptake (90).  
It is known that neurotransmitter transporters exist as oligomeric complexes in 
cell, however the function of these complexes are unclear. SERT was initially detected by 
co-immunoprecipitation to form oligomers (99), and it was later discovered that DAT 
also forms dimers (33) . Additional studies using fluorescence resonance energy transfer 
(FRET) revealed DAT oligomers are formed in the ER and are continually maintained at 
the cell surface and during trafficking events between the plasma membrane and 
endosomes (100). Furthermore, oligomer formation is important for proper targeting of 
newly synthesized DATs to the plasma membrane (101). The LeuT crystal structure 
determined the dimer interface was formed by EL2, TM9, and TMD12 (44).  
 More recently, studies suggest a role for oligomerization in regulating DA 
transport function. It was discovered that substrates of DAT including DA and 
amphetamine, are involved in dissociation of DAT oligomers, shifting the distribution of 
surface DAT from oligomers to more monomers (102). From these studies, it was 
suggested that substrate induced internalization could be mediated by DAT monomers 
(102). Additionally, studies have found the formation of oligomers affects the binding 




Regulation of DAT by lipids 
Integral membrane proteins can segregate into plasma microdomains known as 
membrane rafts. Membrane rafts are small 10-200 nm domains that are highly enriched in 
cholesterol and sphingolipids (104). These microdomains are important for scaffolding 
processes such as receptor signaling.  These small, highly dynamic rafts can sometimes 
be stabilized to form larger microdomains through protein-protein and lipid-protein 
interactions (104). Several membrane proteins are functionally regulated through their 
association with membrane rafts, including serotonin, norepinephrine, and glutamate 
transporters (105–107).  
DAT has also been found to be associated with membrane microdomains, with a 
relatively equal distribution between membrane rafts and non-raft domains (108, 109). 
Studies have shown cholesterol is important for transport activity of DAT. Depletion of 
cholesterol by methyl β cyclodextrin (mβCD) results in a significant decrease in DA 
uptake (108, 109), lowering both DAT’s affinity for DA and the Vmax (109). Membrane 
mobility and microdomain association of DAT has also studied by fluorescence recovery 
after photobleaching (FRAP). Adkins et. al demonstrated that cholesterol depletion 
significantly reduces membrane lateral diffusion of DAT, indicating DAT is more mobile 
(109). Together these studies indicate association of DAT with lipid microdomains 
regulates both lateral membrane mobility of the transporter and transport capacity.  
 Additional studies have focused on the direct interaction of cholesterol and DAT. 
Research has shown that cholesterol can modulate the transporter into an outward facing 
conformation with moderate increases in membrane cholesterol content, allowing for 
increased binding sites for radiolabeled cocaine analogs and enhanced sulfhydryl 
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accessibility to cysteines (51).  Additional studies have shown that disruption of 
membrane cholesterol by mβCD in both raft and non-raft membrane domains results in 
reduced efflux rate (110). Together, these studies suggest an important role for direct 
DAT-cholesterol interactions, vital for the regulation of transporter function (51, 110).  
Cholesterol can interact with many proteins through Cholesterol Recognition 
Amino Acid Consensus (CRAC) motifs The specific sequences L/V-X(1-5)-Y-X(1-5)-K/R 
can bind sterols via hydrophobic aromatic and H-bonding interactions (111). These 
particular CRAC motifs are found in DAT in TMD1, TMD4, TMD6, TMD7, TMD12, 
and the C terminus (68). These sequences are also highly conserved in NET and SERT. It 
is unknown if theses CRAC motifs are important for interactions between DAT and 
cholesterol binding, however, it would suggest another mechanism for DAT regulation 
via cholesterol.  
Protein Palmitoylation 
Many proteins, especially those associated with membrane rafts, are modified by 
palmitoylation. S-palmitoylation consists of a thioesterification of a 16-carbon fatty acid 
(palmitate) on a specific cysteine residue. Palmitoylation increases protein 
hydrophobicity, mediates protein-lipid bilayer interactions, and can alter protein sorting, 
function, and regulation (112–116). Specifically for membrane proteins, palmitoylation 
has been shown to affect the conformation of TMDs by hydrophobic matching, promote 
association with lipid microdomains, promote the formation of protein complexes, and 
affect the interplay with other posttranslational modifications (117–121) (Figure 7). 
Unlike myristoylation and prenylation, which are stable and permanent lipid 




Figure 7: Effects of palmitoylation on transmembrane proteins. (A) Palmitoylation (red 
rectangle) of transmembrane proteins (yellow cylinder), can promote protein-protein 
interactions by modifying the conformation of the protein. (B) Palmitoylation can inhibit 
protein-protein interactions by changing the conformation of the protein. (C). 
Palmitoylation can promote proteins to associate with specific microdomains. (D) 
Palmitoylation group change the conformation of the protein by tilting the TMD.  Image 
modified from Charollais J & Van Der Goot GF. 2009: Palmitoylation of membrane 




reversible. For many proteins, cycles of palmitoylation and depalmitoylation occur 
throughout their lifetime (122). Palmitoylation-depalmitoylation cycles can be 
constitutive or dynamically regulated by signaling events (123, 124), like 
phosphorylation.  
 Palmitoylation is catalyzed by palmitoyl acyltransferases (PATs) while 
depalmitoylation is catalyzed by palmitoyl-protein thioesterases (PPTs). PATs are poly-
topic membrane proteins (125, 126), suggesting that palmitoylation reactions generally 
occur near the cytosol membrane interface (127). Systematic screening has recently 
identified a large family of PAT enzymes in the human genome (112, 125, 128–130), 
also known as the DHHC enzymes. The PAT enzymes are characterized by the presences 
of a 50 amino acid cysteine rich domain that contains a conserved amino acid sequence 
Asp-His-His-Cys (DHHC) in the active site (130). Besides the DHHC core domain, these 
proteins also contain four or more TMDs, with the DHHC domain usually located 
between TMD2 and TMD3 (113, 126, 131, 132) (Figure 8). Additionally, some DHHC 
enzymes have individual protein-protein interacting domains such as a PDZ-binding 
domain (DHHC3 and DHHC8); SH3 domain (DHHC6); or ankyrin repeats (DHHC13 
and DHHC17) (113, 126, 131) (Figure 6). Additionally, The 23 PATs have varied tissue 
distributions and intracellular localizations, with most being localized to the Golgi 
apparatus, endoplasmic reticulum, or the plasma membrane (132, 133). The large number 
of DHHC proteins along with their localization to specific cellular compartments 
suggests that palmitoylation machinery is tightly regulated and highly controlled. 
In contrast to the large number of DHHC enzymes that catalyze palmitoylation, 




Figure 8: Domain structure of DHHC enzymes found in the brain. A representative diagram 
of DHHC (Asp-His-His-Cys) proteins. DHHC enzymes contain four or more 
transmembrane domains (pink squares) and a conserved cysteine rich domain (CRD) 
containing a DHHC motif (yellow rectangles), which is essential for palmitoylation. Some 
enzymes have additional motifs including a PDZ binding domain (orange cylinders) at the 
C terminus for DHHC3 and DHHC8, and ankyrin repeats (green rectangles) for and 
DHHC17. Image modified from Koryckaa J, Lacha Am Hegerb E, Boguslawskab DM, 
Wolnya M, Toporkiewixza M, Augoffc K, Korzeniewskid J, and Sikorskia AF 2012. 
Human DHHC proteins: A spotlight on the hidden player of palmitoylation European 
Journal of Cell Biology 91: 107-117, with permission 
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acyl protein thioesterases 1 (APT1), APT2, and APT1-like and and palmitoyl protein 
thioesterases 1 (PPT1) and PPT2. APTs are cytosolic enzyme that removes palmitate 
from proteins on the cytosolic membranes (122). PPT1 and PPT2 are lysosomal proteins 
(134) that are important for depalmitoylating proteins during protein degradation. 
Because PPT1 and PPT are lysosomal proteins they do not directly act on cytosolic 
palmitoylated proteins (135). However, PPT1 has been detected in the presynaptic 
compartments, where it is suggested to be important for maintaining the synaptic vesicle 
pool (136). 
 There is no defined consensus sequences for substrate palmitoylation, however, 
palmitoylated proteins do share common features (127). Palmitoylated proteins often 
have other lipid modifications such as myristoylation or prenylation, located near the site 
of palmitoylation. Also palmitoylated Cys residues are located in the cytoplasmic regions 
surrounding TMDs and are surrounded by amino acids that are basic or hydrophobic. The 
mechanism by which a substrate protein is palmitoylated occurs in a two-step process 
(137). First the DHHC enzyme modifies itself with palmitate, in a process known as 
autoacylation, then the enzyme transfers the palmitate from itself onto the substrate 
protein (138, 139). Until recently it was unknown where autoacylation occurred. Mass 
spectrometry studies have now identified the Cys in the DHHC motif as the site of 
autoacylation (140). 
Although the enzymes that control palmitoylation, have been identified, little is 
currently known regarding mutations or regulatory abnormities associated with disease 
states. However, there are a few PAT enzymes that have been associated with 
neurological disorders. DHHC8 is the most well studied DHHC enzyme and has been 
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connected to schizophrenia (141, 142). A high risk of developing schizophrenia is 
associated with microdeletions of human chromosome 22q11.22 locus (141, 142). This 
deleted region also includes the DHHC8 gene. Interestingly, the deficits linked to the 
microdeletion could be rescued by expression of the active DHHC8 protein (141), 
indicating the importance of palmitoylation. Furthermore, PATs represent a potential 
therapeutic strategy for some diseases.  
Huntington’s disease is also another neurological disorder linked to DHHC 
enzymes(143). Huntington’s disease is caused by the expansion of polyglutamine 
(polyQ) repeats in the huntingtin protein (143, 144). Additionally, Huntington’s disease is 
characterized by the accumulation of protein aggregates that are formed by the misfolded 
polyQ repeat-containing proteins. Normally, the protein huntingtin is palmitoylated by 
DHHC17, however the polyQ expression of huntingtin disrupts the interaction with 
DHHC17, resulting in decreased palmitoylation (144). Reduced palmitoylation causes 
accumulation of protein aggregates in inclusions which may be correlated with cell 
toxicity (132, 143, 144).  
Other DHHC enzymes linked to neurological disease include DHHC9 and 
DHHC15. Both enzymes have been associated with X-linked intellectual disability in 
humans (145, 146). Although the exact cause is unknown, mutations in the conserved 
DHHC9 and DHHC15 genes have been found in families with the X-linked intellectual 
disability phenotypes. Initial studies suggest proper palmitoylation is required for the 
temporal and spatial location of proteins in the plasma membrane and Golgi complex. 
Loss of palmitoylation alters the distribution of target proteins and is sufficient enough to 
cause X-linked intellectual disability (132, 146). 
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Depalmitoylation has also been linked to neurodegenerative diseases (147). The 
autosomal recessive brain disorder, infantile neuronal ceroid lipofuscinosis is cause by a 
mutation of in PPT1(147, 148). Mutations in the lysosomal PPT1 enzyme impairs the 
removal of long chain fatty acids from proteins, preventing protein degradation, and 
resulting in the accumulating of palmitoylated proteins(124, 144, 148).  
DAT Palmitoylation 
 Our lab demonstrated for the first time that DAT undergoes palmitoylation in both 
native and heterologously expressed tissues (149). This modification was blocked with 
the treatment of the irreversible PAT inhibitor 2-bromo palmitate (2BP). In this same 
study it was determined that 2BP regulates DAT palmitoylation in two distinct ways. A 
low dose and shorter 2BP treatments resulted in a significant reduction in DA transport 
Vmax with no changes in surface expression. These results indicate reduced DAT 
palmitoylation decreases transport kinetic efficiency, affecting short-term regulation of 
DAT. A higher dose and longer treatment with 2BP caused DAT protein losses, 
indicating DAT palmitoylation is also regulated long-term.  
 There are five intracellularly oriented cysteines residues that are potential sites of 
DAT palmitoylation in rDAT (Cys6, Cys135, Cys341, Cys522, and Cys580). Through 
mutagenic studies, it was determined the major site of DAT palmitoylation is at Cys580 
in rDAT. Metabolic Labeling of the C580A mutant with [3H]palmitate, reduced DAT 
palmitoylation by ~60% compared to the WT protein. The [3H]palmitate signal remaining 
on C580A suggests one or more additional site is palmitoylated in rDAT. Additional 
studies determined the C580A palmitoylation-deficient mutant still had cocaine-
displaceable [3H]DA transport activity that was proportional to the overall expression. 
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When immunoblotted, the C580A mutant resulted in low molecular weight degradation 
fragments that were not visualized in the WT protein. These fragments were enhanced 
when C580A rDAT cells were treated with 2BP, suggesting palmitoylation is important 
for opposing DAT degradation. The C580A mutant also displayed increased PMA-
induced down-regulation compared to WT, indicating depalmitoylated DAT is more 
sensitive to PKC- induced down regulation compared to palmitoylated DAT (149).  
More recently our lab has shown palmitoylation to play a reciprocal role with 
phosphorylation (150). To study this process, the C580A palmitoylation mutant and the 
S7A phosphorylation mutant were assessed for either palmitoylation or phosphorylation 
levels of DAT. The C580A mutant had significantly enhanced DAT phosphorylation 
levels in comparison to WT. In reverse experiments, the S7A mutant had increased DAT 
palmitoylation level when assessed by [3H]palmitate labeling. Together, these mutagenic 
studies suggest that both of these posttranslational modifications may be important in 
regulating DAT activity. Additional pharmacological experiments were done to confirm 
the mutagenic results. In these experiments, cells were treated either with PMA, which 
stimulates PKC and thus DAT phosphorylation, or bisindolmaleimide (BIM), which 
blocks PMA-stimulated DAT phosphorylation (36). PMA significantly reduced [3H] 
palmitate labeling, while treatment with BIM increased it, suggesting palmitoylation and 
phosphorylation are working opposite of each other in an unknown mechanism. In 
reverse experiments, rat striatal synaptosomes were used to determine the DAT 
phosphorylation state in depalmitoylated conditions. Results showed 2BP treatment 
caused a significant increase in DAT phosphorylation compared to basal levels.  Taken 
together, the mutational and pharmacological experiments demonstrate that these 
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posttranslational modifications are reciprocally regulated and important for DAT 
regulation and function. 
 Purpose of Current Study 
The dopamine transporter has been found to be palmitoylated on the C-terminus at 
Cys580 (149). This posttranslational modification is known to regulate diverse aspects of 
neuronal protein trafficking and function (132, 151), however its role in DAT function is 
poorly understood. DAT palmitoylation was previously found to be inhibited by the non-
specific PAT inhibitor, 2BP. Treatment with 2BP resulted in decreased  DA transport 
activity and an increase in DAT degradation (149), suggesting palmitoylation controls 
one or more functions of DAT. 
There are 23 PAT enzymes currently identified in the human genome (112, 125, 128–
130), with some associated with dopaminergic diseases such as schizophrenia (141, 142); 
however, the enzymes that catalyze DAT palmitoylation still remain unknown. 
Furthermore, psychostimulant drugs such as METH and cocaine are known to act on 
DAT, effecting transporter function (69, 70, 73, 75, 76, 152). Nonetheless, the effects of 
psychostimulant drugs on DAT palmitoylation still remain unknown. Therefore, we 
hypothesized that specific PAT enzymes will drive DAT palmitoylation, controlling 
expression, DA transport, and membrane lateral mobility of the transporter. To answer 
this question, we co-expressed a specific subset of neuronally-expressed PATs 
individually with DAT and assessed DAT palmitoylation using the acyl-biotinyl 
exchange method, with some results validated by [3H]palmitic acid labeling. Functional 
changes of DAT were also assessed including, total and surface expression, transport 
activity, and lateral membrane mobility. Additional studies were also conducted to 
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investigate psychostimulant regulation of DAT palmitoylation. Identifying the enzymes 
that drive DAT palmitoylation will allow us to better understand the mechanism of 
palmitoylation, thus providing critical insight into dysregulation in dopaminergic 









 Male Sprague Dawley rats (200-300g) were obtained from Charles River 
Laboratories (Wilmington, MA) and were maintained in compliance with the guidelines 
established by the University of North Dakota Institutional Animal Care and Use 
committee and the National Institutes of Health.  
Reagents 
Methyl methanethiosulfonate (MMTS), (N-(6-(biotinamido) hexyl)-3-(2’-pyridyldithio)-
propionaminde (HPDP biotin), high capacity Neutradvidin resin, Complete Mini 
Proteases Inhibitors, DHHC2 antibody, X-treme GENE HD, Lipofectamine2000, Opti-
MEM, and Trypsin were purchased from Thermofisher Scientific (Waltham, MA). [7,8-
3H] dopamine (45Ci/mmol) was purchased from Perkin Elmer (Walthman, MA). [9,10-
3H] palmitic acid was purchased from Moravek (Brea, CA).  Protein A Sepharose beads 
were purchased from GE Healthcare Life Sciences (Piscataway, NJ). (-)-Cocaine, (-) 2β-
carbomethoxy-3β-(4-fluorophenyl) tropane (β-CFT), mazindol, dopamine, 
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hydroxylamine, molecular weight markers were purchased from Sigma-Aldrich (St. 
Louis, MO).  Lewis Lung Carcinoma Porcine Kidney (LLCPK1) cells expressing rDAT 
were kindly provided by Dr. Gary Rudnick (Yale University, New Haven, CT). Neuro-2a 
(N2a) cells were purchased from American Type Culture Collection (ATTC) (Manassas, 
VA). The DHHC constructs were kindly provided by Dr. Masaki Fukata from the 
National Institute for Physiological Sciences, Okazaki, Aich Japan. Hemagglutinin 
epitope HA.11 monoclonal antibody was purchased from Covance (Emeryville, CA). 
DHHC3, DHHC8, DHHC9 antibodies were purchased from Santa Cruz Biotechnology 
(Dallas, TX). Transferrin Receptor (TfR) antibody was purchased from BD Biosciences 
(San Jose, CA). Alkaline phosphatase conjugated secondary antibody were purchased 
from Simga-Aldrich (St. Louis, MO). Polyacrylamide gels were purchased from Lonza 
(Rockland, ME). Alkaline phosphatase developing substrate was purchased from Bio-
Rad (Hercules, CA). Site directed mutagenesis Quick Change® kit was from Stratagene 
(La Jolla, CA). Synthesized oligonucleotides were purchased from Eurofin MWG Operon 
(Huntsville, AL). All other chemicals were purchased from Sigma-Aldrich (St. Louis, 
MO) or Thermofisher Scientific (Waltham, MA).  
Equipment 
Centrifuges 
Refrigerated Beckman microfuge R or the bench top Microfuge 18 were used for 
general lab procedures. The Beckman Avanti J-25, 16.250 and 25.50 rotors were used for 
synaptosome preparation and harvesting E.Coli cells for protein and plasmid isolation 
purposes. The Beckman J6-MI swinging bucket centrifuge was used to pellet cells and to 




 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
protein transfers were performed using the Bio-Rad Mini-Protein III electrophoresis 
apparatus and the Bio-Rad Mini trans blot electrophoresis transfer cell, respectively. 
Electrophoresis and protein transfer was controlled by Fisher Scientific FB300 power 
supply. Gels were dried using a Bio-Rad Model 583 gel dryer. 
Spectroscopy  
  Bicinchoninic acid (BCA) protein assays were quantified using the Molecular  
Devices SpectraMax 190 plate reader and DNA quantification was performed using  
Beckman DU640 spectrophotometer. Incorporation of radioactivity during uptake 
experiments were counted using a Packard 1900CA or a Beckman LS6500 liquid 
scintillation counter. 
Cell Culture and Molecular Biology 
Mammalian cell were maintained in a sterile Nuair Class II A/B3 laminar flow 
hood, and incubated in a Nuair 2700-30 water jacketed CO2 incubator. All Polymerase 
Chain Reactions (PCR) experiments were done in an Eppendorf Mastercycler personal 
thermal cycler.  
Microscopy 
Confocal and Fluorescence recovery after photobleaching (FRAP) experiments 





Mammalian Cell Culture 
Lewis lung carcinoma-porcine kidney (LLCPK1) cells stably expressing the WT 
rat dopamine transporter (rDAT) were maintained with α- minimum essential medium 
(AMEM) supplemented with 5% fetal bovine serum, 2 mM L-glutamine, 100 µg/ml 
penicillin/streptomycin, and 200ug/ml G418. Neuro-2A cells (N2a) cells were maintained 
with α- minimum essential medium (AMEM) supplemented with 10% fetal bovine 
serum, 2 mM L-glutamine, 100 µg/ml penicillin/streptomycin. All cells were grown in T-
75 flasks and maintained at 37°C in a 5% CO2 in the Nuair water-jacketed CO2 incubator.   
Transient Transfection and Site Directed Mutagenesis, and Plasmid Transformation 
For transient transfection, LLCPK1  or N2a cells were grown to ~70 % confluency 
and transfected using X-tremeGENE HD or lipofectamine 2000 transfection reagent and 
2 µg of PAT DHHC pEF-BOS-HA tagged plasmid. Cells were incubated for 18-20 hours 
followed by harvesting. Site-directed mutagenesis of DHHC2 to DHHA2 was performed 
on pEF-BOS-HA plasmid containing Stratagene design primer software was used to 
design oligonucleotide primers, which were ordered from MWG operon. QuickChange® 
method was used to mutant selected residues C156. A 50 µL reaction mixture included 5 
µL of 10X reaction buffer (100 mM KCl, 100 mM NH4SO4, 200 mM Tris-HCl, 20mM 
MgSO4, 1% Triton X-100, 1 mg/mL nuclease free BSA, pH 8.8), 8 µL of template DNA 
(5 ng/µL), 1.25-1.60 µL of oligonucleotide forward and reverse primers (125 ng), 2µL of 
dNTP mix, 32.5 – 31.8 µL of double distilled DNAse free H2O.  Addition of 1 µL of pfu 
Turbo or pfu Ultra DNA Polymerase (2.5 U/µL) initiated the polymerase chain reaction 
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(PCR). PCR cycling parameters included denaturation, annealing, and primer extension. 
Denaturation required heating the DNA to 95 ºC for 1 min to render it single stranded. 
The annealing step was performed at 55 ºC for 1 min and primer extension was done at 
68 ºC for 8 min followed by 15 repeated denaturation, annealing, and primer extension 
cycles. Supercoiled double stranded template DNA was degraded by incubation with 1 
µL of DpnI restriction enzyme for 18 h at 37 ºC. The generated plasmid was transformed 
into Stratagene Giga competent E coli cells. 1-4 µL of ligation mixture was added to 25 
µL of competent cells. Cells were placed on ice for 5 min and heat shocked for 30 sec at 
42 ºC on a heat block. Tubes were placed on ice for 2 min and 250 µL of SOC media was 
added and cells were plated on carbenicillin resistant agar plates for > 16 h at 37 ºC. The 
plasmid was isolated using PureYield® Plasmid miniprep System (Promega). DNA was 
quantified via Epoch microspot spectrometry and sent to MWG operon (Birmingham, 
AL). 
Cell Membrane Isolation 
LLCPK1  rDAT or N2a cells were grown in 100 mm plates and harvested when 
reaching 90% confluency. Cells were washed twice (0.25 M sucrose, 10 mM 
tiethanolamine, 10 mM acetic acid, pH 7.8) at 4°C, scraped, and pelleted at 700 X g for 8 
mins. Cells were then resuspended in buffer C (0.25 M sucrose, 10 mM triethanolamine, 
10 mM acetic acid, 1 mM EDTA, pH 7.8), transferred to a Dounce homogenizer, and 
homogenized. Homogenate was centrifuged at 700 X g for 10 mins. For membrane 
isolation the supernatant fraction was further centrifuged and 16,000 X g  for 12 min and 




Analysis of DAT Palmitoylation by Acyl-Biotinyl Exchange 
DAT palmitoylation was assessed by ABE using a method modified from Wan et 
al. (153). LLCPK1 rDAT or N2a cells were harvested followed by centrifugation at 
20,000 x g for 12 mins at 4C. Cell pellets were solubilized in lysis buffer (50  mM 
HEPES, pH 7.0, 2% SDS, 1 mM EDTA) containing Mini Complete protease inhibitor 
and 20 mM MMTS to block free thiols.  Lysates were incubated at room temperature for 
1 hour with mixing followed by acetone precipitation and resuspension in lysis buffer 
containing MMTS and incubation again for 1 hour at room temperature followed by 
acetone precipitation and resuspension in lysis buffer and incubated at room temperature 
overnight with end-over-end rotation. Excess MMTS was removed by three sequential 
acetone precipitations followed by resuspension of the precipitated proteins in 300 µl of 
4SB (4% SDS, 50 mM Tris, 5 mM EDTA, pH 7.4). Each sample was divided into two 
equal portions and treated for 2 hours at room temp with 50 mM Tris-HCL, pH 7.4 or 0.7 
M hydroxylamine, pH 7.4 to cleave thioester linkages. Hydroxylamine was removed with 
three sequential acetone precipitations followed by resuspension of pellet in 240 µl of 
4SB, and diluted with 50 mM tris containing 0.4 mM sulfhydryl-reactive (N-
(6(biotinamido)hexyl)-3`-(2`-pyridyldithio)-pro-pionamide (HPDP)  for 1 hour at room 
temp. Excess HPDP was removed by three sequential acetone precipitations followed by 
resuspension of pellet in 75 µl of lysis buffer without MMTS. 10 µl of the sample was 
save for total DAT and the remaining 65 µl was diluted with 50 mM Tris-HCL, pH 7.4 to 
contain 0.1% SDS. Samples were affinity-purified using Neutravidin resin overnight with 
end-over-end rotation at 4°C. Proteins were eluted with sample buffer (60 mM Tris, pH 
6.8, 20% SDS, 10% glycerol) containing 100 mM DTT and 3% β-mercaptoethanol and 
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subjected to SDS-PAGE and immunoblotting with DAT monoclonal antibody 16 
(mAb16). Palmitoylated DAT protein was normalized to total DAT protein.  
Analysis of DAT Palmitoylation by [3H] Metabolic labeling 
LLCPK1  rDAT cells were metabolically labeled with [9,10-
3H] palmitic acid (0.5 
mCi/ml) for 18 hours at 37C in AMEM media. After labeling, cells were lysed in 
radioimmunoprecipitation assay buffer (RIPA: 10 mM sodium phosphate, 150 mM NaCl, 
2 mM EDTA, 1% Triton X-100, , 0.1% SDS, pH 7.2). Metabolically labeled samples 
were normalized to equal amounts of DAT first by immunoblotting with mAb16 then 
immunoprecipitated with polyclonal Ab16.  Precipitated proteins were then resolved on 
4-20%  SDS-polyacrylamide gels with Rainbow molecular mass markers followed by 
soaking gels in Fluro-Hance (Research Products International) fluorographic reagent for 
30 min, dried, and exposed to pre-flashed x-ray film for 30-90 days. Band intensities 
were quantified using Quantity One software (Bio-Rad), and values were normalized to 
total DAT levels.   
Immunoprecipitation and SDS-PAGE Western Blot 
DAT immunoprecipitation and immunoblotting were performed using polyclonal 
or monoclonal antibody 16 (154, 155).  Samples were resolved on 4-20% SDS-PAGE 
gels with Rainbow molecular mass markers then proteins were transferred to PVDF 
membranes. Immunoreactive bands were visualized using Immuno-Star AP substrate and 






For surface biotinylation LLCPK1 or N2a cells were transiently transfected with 
co-expressed rDAT and DHHC enzymes. Cells were washed three times with ice cold 
Hank’s buffer salt solution (HBSS) Mg-Ca (HBSS, 1mM MgSo4, 0.1 mM CaCl2, Ph 
7.4), incubated twice with 0.5mg/mL of membrane-impermeable reagent, sulfo-NHS-SS-
biotin for 25 min each at 4°C. The biotinylation reagent was removed and the reaction 
was quenched by two sequential incubations with 100 mM glycine in HBSS Mg-Ca for 
20 min each at 4°C. Cells were then washed with HBBS Mg-Ca and lysed with RIPA 
containing a Complete Mini protease inhibitor tablet/10 ml. Equal cell lystes (100 ug 
protein) samples were affinity-purified using Neutravidin resin overnight with end-over-
end rotation at 4°C. The beads were washed three times with RIPA buffer and the bound 
protein was eluted with 32 µl of sample buffer followed by immunoblotting with mAb16. 
Surface localization of biotinylated DAT protein was confirmed by probing blot for 
intracellular protein using anti protein-phosphatase 1 α (PP1α) antibody. For some 
experiments samples were probed for anti-transferrin receptor. Surface expression was 
normalized to total DAT or total transferrin receptor.  
[3H] DA Uptake Assay 
LLCPK1 expressing WT rDAT or N2a cells transiently transfected with WT 
rDAT and DHHC enzymes were grown to 80-90% confluence. Cells were washed twice 
with Krebs-Ringer HEPES (KRH) buffer (25 mM HEPES, 125 mM NaCl, 4.8 mM KCl, 
1.2 mM KH2PO4, 1.3 mM CaCl2, 1.2 mM MgSO4, 5.6 mM glucose, pH 7.4). Interval 
DA uptake was initiated by adding 10 µl of a 100X DA stock solution to bring the final 
concentration of [3H] DA to 10 nM and that of total DA to 3 µM.  Nonspecific uptake 
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was determined by addition of 100 µM (—) –cocaine. Uptake assay was performed at 
37°C for 8 minutes and terminated by rapidly washing the cells two times with ice-cold 
KRH buffer. Cells were solubilized in RIPA containing protease inhibitor tablet. 
Radioactivity contained in lysates was measured by liquid scintillation counting. Uptake 
activity was normalized to total protein as determined by BCA assay.  
Subcellular localization of palmitoylated DATs 
Subcellular fractions were generated by differential centrifugation LLCPK1 cells 
stably expressing WT rDAT were cultured in 150 mm dishes, grown to ~90%. Cells were 
washed, scraped, and pelleted by centrifugation at 700 x g for 5 min at 4 °C. Pelleted 
cells were resuspended in Buffer C (0.25M sucrose, 10 mM triethanolamine, 10 mM 
acetic acid, 1 mM EDTA, pH 7.8) and homogenized in ice-cold Buffer C with 30 strokes 
in a Dounce homogenizer. Homogenates were centrifuged at 700 x g to remove nuclei, 
and post- nuclear supernatants (totals), were centrifuged sequentially at 16,000 x g for 12 
min (16,000 x g membranes), and at 200,000 x g for 1h (200,000 x g membranes). 
Resulting pellets were resuspended at the original volume in RIPA buffer containing 
protease inhibitors. Fractions were immunoblotted for DAT, Na+/K+ ATPase, Rab5A, 
Rab7, and Rab11, or analyzed by ABE for detection of DAT palmitoylation. 
Fluorescence Recovery After Photobleaching (FRAP) 
FRAP studies were done with a Zeiss 510 META laser scanning confocal 
microscope. N2a cells were grown to ~50% on 1 mm glass coverslips and transiently 
transfected with EYFP WT rDAT and individual HA-tagged DHHC enzymes. Spot 
photobleaching using circular regions of interest 30 µm in diameter were placed on the 
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membrane of the visualized cell, followed by bleaching of the region using the 514 nm 
laser at 100% power to obtain 50-70% bleaching. Images were at collected at 2% laser 
power in 3.93 sec intervals for a duration of 5 mins totaling 100 images. The images were 
processed in ImageJ and recovery curves were calculated. The rate of recovery (t ½) was 
calculated from an exponential recovery function (F(x)=F”∞”+A(exp9-XT)) fitted to the 
fluorescence recovery data.  
In vivo Analysis of DAT Palmitoylation in Rats 
Male Sprague Dawley rats (175-350g) were subcutaneously (SC) injected with 
saline (control), METH (15 mg/kg), or cocaine (15 mg/kg) for 10, 30, 60 min post SC 
injection. The animals were decapitated and the striata rapidly removed, weighed and 
place in ice-cold 0.32 M SP buffer. Striatal tissue was homogenized with a Polytron 
PT1200 homogenizer (Kinematica, Basel, Switzerland) for 8 seconds and centrifuged at 
3,000 x g for 3 min at 4 ºC. The supernatant was then centrifuged at 16,000 x g for 12 
min. The resulting pellet was resuspended in modified Krebs phosphate buffer (126 mM 
NaCl, 4.8 mM KCl, 16 mM KPO4, 1.4 mM MgSO4, 10 mM glucose, 1.1 mM ascorbic 
acid, and 1.3 mM CaCl2, pH 7.4) to 20 mg/ml original wet weight. The membranes were 





Identification of DAT Palmitoyl Acyl Transferases 
Protein palmitoylation is known to regulate many diverse aspects of neuronal 
protein trafficking and function (112, 113, 120, 156), however its role in DAT function is 
poorly understood. Furthermore, 23 PAT enzymes that have been identified in the human 
genome (112, 125, 128–130), yet the enzymes that catalyze DAT palmitoylation still 
remain unknown. Previous studies have shown that DAT is palmitoylated and that 
inhibition of DAT palmitoylation affects the function of the transporter (149), therefore 
identifying the enzymes that drive palmitoylation is of great interest. The mammalian 
PAT enzymes have varying tissue and subcellular distribution, and a few, if any, specific 
pharmacological activators or inhibitors for these enzymes, making the identification of 
PATs that catalyze DAT palmitoylation difficult. To determine which PATs play a role in 
DAT palmitoylation we choose a specific subset of DHHC 2, 3, 5, 7, 8, 9, 11, 15, 17, 20, 
21, and 22, known to be expressed in a neuronal context or those associated with 
neurological disorders. In our initial studies, we wanted to determine in a model cell 
system if we could co-express the DHHC enzymes with DAT. For these studies, LLCPK1 
cells expressing wild type (WT) rDAT were transiently transfected with individual HA-




Figure 9: DHHC expression in rDAT LLCPK1 cells. rDAT LLCPK1 cells were transiently 
transfected with the indicated HA-tagged DHHC coding plasmids for 18 h. Cells were 
immunoblotted for DAT (mAB16) and DHHC expression (anti-HA). GST tagged plasmid 






Figure 10: Acyl-biotinyl exchange method. The ABE method consists of three major steps: 
blockade of unmodified free Cys thiols with MMTS; cleavage of palmitoylation thioester 
linkages with NH2OH; and labeling of newly exposed Cys thiols with a thiol specific 
biotinylation reagent. Biotinylated proteins are extracted with NeutrAvidin agarose 
followed by SDS-PAGE and immunoblotting for DAT. Image modified from Yuko Fukata 
and Masaki Fukata. 2010. Protein palmitoylation in neuronal development and synaptic 





Figure 11: Multiple DHHC enzymes increase DAT palmitoylation. rDAT LLCPK1 cells 
transiently transfected with the indicated DHHC coding plasmids were harvested and 
membranes isolated, followed by assessment of DAT palmitoylation by ABE. Upper 
panels show representative ABE blots with matching total DAT immunoblots for increased 
palmitoylation (A and B) and for no effect (C). Histogram represents quantification of 
palmitoylated DAT normalized for total DAT protein expressed as a fraction of control 
values normalized to 100% (means ± S.E. of 3-4 experiments performed in triplicate).  * 
p< 0.05, ** p<0.01 relative to control by (one-way ANOVA with Dunnett’s Post hoc test). 
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the National Institute for Physiological Sciences, Okazaki, Aich Japan. DHHC co-
expression was verified by immunoblotting cell lysates 18 h post transfection using an 
anti-HA antibody (Figure 9). The DHHC enzymes and DAT were easily detectable, 
indicating successful co-expression of these proteins in our mammalian cell system. The 
same vector containing the coding sequences for GST was used as a transfection control 
(Figure 9 far right).  
To determine which PATs play a role in DAT palmitoylation, experiments were 
performed by comparing DAT palmitoylation in the presence of co-transfected DHHCs. 
For most experiments, DAT palmitoylation was analyzed by the in vitro acyl-biotinyl 
exchange (ABE) method. In this method, samples are treated with methyl 
methanethiosulfonate (MMTS) to block free thiols, followed by treatment with 
hydroxylamine (NH2OH) to remove thioester-linked palmitate, with parallel samples 
treated with Tris-HCl (control), and finally the newly exposed cysteine thiols were 
labeled with a sulfhydryl-reactive biotin for NeutrAvidin extraction followed by SDS-
PAGE and immunoblotting for DAT. The method is depicted in Figure 10.  
Our findings (Figure 11) show that DAT palmitoylation is enhanced relative to 
control by over-expression of DHHC2 (141.6 ± 12%, p<0.001), DHHC3 (127.8 ± 7%, 
p<0.01), DHHC8 (138.7 ± 12%, p<0.001), DHHC15 (132.4 ± 6%, p<0.001), and 
DHHC17 (121.9 ± 4% p<0.05). Several other co-expressed DHHC enzymes (DHHC5, 7, 
9, 11, 20, 21, and 22) however had no effect on DAT palmitoylation (p>0.05), indicating 
a substrate specific. It is also important to note that the immature form of DAT was also 
palmitoylated (not shown) in all cases. Taken together, these results indicate that multiple 













Figure 12: DHHC2-induced DAT palmitoylation validated by [3H]palmitic acid labeling. 
rDAT LLCPK1 cells were transiently transfected with HA-tagged DHHC2 coding plasmid. 
After four hours, media was removed and cells were metabolically labeled with 
[3H]palmitic acid for 18 h. Cell lysates were immunoprecipitated followed by SDS-
PAGE/fluorography. Upper panel shows representative results for autoradiogram (top) and 
western blot of total DAT (bottom). Histogram represents quantification of means ± S.E 
three independent experiments performed in triplicate relative to control normalized to 
















Figure 13: Enzymatic activity of DHHC2 is required for increased DAT palmitoylation. 
ABE analysis of rDAT LLCPK1 cells transiently transfected with DHHC2 or C→A 
mutation DHHA2. Upper panel shows representative results for ABE. Histogram 
represents quantification of palmitoylated DAT normalized for total DAT protein 
expressed as a fraction of control values normalized to 100% (means ± S.E. of four 
independent experiments performed in duplicate). ** p< 0.01, *** p<0.001 relative to 
control by (one-way ANOVA with Tukey’s post hoc test) 
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To confirm our ABE results, we performed metabolic labeling with [3H]palmitic 
acid (Figure 12). LLCPK1 cells stably expressing WT rDAT were transiently transfected 
with HA-tagged DHHC2 and labeled with palmitic acid. Co-expression with DHHC2 
significant increased DAT [3H] palmitoylate labeling relative to control (138 ± 11% versus 
control, p <0.05). Although this method is known to be less sensitive (157), the increases 
in DAT palmitoylation was similar to the results obtained by ABE. These results confirm 
that DAT palmitoylation is driven by the overexpression of DHHC enzymes.  
 To demonstrate that acyl transferase activity in the co-expressed DHHC was 
necessary for increased DAT palmitoylation, an inactive DHHA2 enzyme was utilized 
(158). Site directed mutagenesis was used to converted DHHC2 to DHHA2, changing the 
Cys at position 156 to an Ala, making the enzyme inactive (158). Expression levels of the 
mutant DHHA2, determined by anti-HA immunoblotting was equivalent to the WT 
DHHC2 (Figure 9 far right). Co-expression with WT DHHC2 significantly increased 
DAT palmitoylation (p<0.001) compared to control, however DHHA2 resulted in no 
change in DAT palmitoylation (DHHA2 78.8 ± 3% relative to control p>0.05), and was 
significantly different from the WT DHHC2 enzyme (p<0.001) (Figure 13). These results 
indicate that the enzymatic activity of DHHC2 is required for increased DAT 
palmitoylation.  
Palmitoylation Enhances DAT Expression 
 Previous studies have shown acute or chronic inhibition of palmitoylation by 2BP 
results in increased DAT degradation, as detected by the loss of full-length DAT and 




Figure 14: DAT palmitoylation increases total DAT expression. rDAT LLCPK1 cells 
were transiently transfected individually with HA-tagged DHHC coding plasmids for 18h 
equal amounts of protein were immunoblotted for DAT.  Top panel shows representative 
immunoblots and histogram shows band density expressed as a fraction of control values 
normalized to 100% (means ± S.E. of 4 independent experiments performed in 
duplicate). *  p<0.05, ** p<0.01, *** p<0.001 versus control. (one-way ANOVA with 




Figure 15: Functional studies in LLCPK1 cells. rDAT LLCPK1 cells were transiently 
transfected with the indicated HA-tagged DHHC coding plasmids and assayed for DA 
uptake activity and surface expression. (A) DA uptake activity normalized to total protein. 
Histogram is presented as means ± S.E. of 3-4 independent experiments relative to control 
normalized to 100% p>0.05 by ANOVA with Dunnett’s post hoc test. (B) Surface 
biotinylation analysis of LLCPK1 cells co-expressing indicated DHHC enzymes. 
Representative immunoblots showing equal amounts of protein analyzed for DAT total and 
surface levels Histogram is presented as means ± S.E. 2 independent experiments relative 




enzymes that drive DAT palmitoylation would also increase total DAT expression. To 
test this, LLCPK1 cells stably expressing WT rDAT were transiently transfected with 
individual DHHC coding plasmids for 18h, and cell lysates immunoblotted for total DAT 
(Figure 14). Results show that total DAT levels were increased by co-expression of 
DHHC enzymes that increase DAT palmitoylation (DHHC2 123 ± 3%, p<0.01; DHHC3 
134 ± 9%, p<0.001; DHHC8 119 ± 1%, p<0.05; DHHC15 121 ± 4%, p<0.05, DHH17 ± 
8%, p<0.01). The DHHC enzymes that had no effect on DAT palmitoylation did not 
increase total DAT expression, (DHHC 5, 7, 9, 11, 20, 21, and 22, p>0.05). Co-
expression with the inactive enzyme DHHA2, which did not increase DAT 
palmitoylation, also resulted in no change in total DAT levels (100 ± 6%, p>0.05), 
supporting the modification of DAT as driving this effect. Together with our previous 
2BP finding, these results demonstrate that palmitoylation opposes DAT degradation. 
Functional Studies of DAT Palmitoylation in LLCPK1 Cells 
 To further understand the role of DAT palmitoylation, we investigated the 
functional effects. Previous studies demonstrated that inhibition of DAT palmitoylation 
with 2BP decreased DA transport activity (149), therefore we hypothesized that increased 
palmitoylation would result in increased DAT activity. To test this LLCPK1 cells stably 
expressing WT rDAT were transiently transfected with indicated DHHC enzymes for 18 
h, followed by assessment for [3H]DA uptake (Figure 15A). Surprisingly, we found that 
DA transport activity was not altered when co-expressed with DHHC enzymes that 
increased DAT palmitoylation (DHHC2 and DHDHC3 p>0.05). Because we did not seen 




Figure 16: DHHC enzymes increase DAT palmitoylation in N2a cells. N2a cells transiently 
transfected with WT rDAT and indicated DHHC coding plasmids were harvested and 
membranes isolated, followed by assessment of DAT palmitoylation by ABE. Upper 
panels show representative ABE blots and matching total immunoblots for increased 
palmitoylation (A) and for no effect (B). Histogram shows quantification of palmitoylated 
DAT normalized for total DAT protein expressed as a fraction of control values normalized 
to 100% (mean ± S.E. of 3-5 experiments performed in duplicate).  * p< 0.05, ** p<0.01 
relative to control by (one-way ANOVA with Dunnett’s Post hoc test) 
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biotinylation to determine if changes in surface expression were occurring (Figure 15B). 
Results indicated no change in surface DAT when normalized to total DAT for all DHHC 
enzymes assessed (DHHC2, 3, 8, and 11 (p.>0.05). Control experiment with AMPH 
resulted in decreased surface biotinylation, indicating internalization of DAT (Figure 15B 
lane 2). These results were unexpected, demonstrating increased DAT palmitoylation does 
not change transport activity or surface expression. Based on previous results (149) we 
predicted changes in DAT palmitoylation would be accompanied by functional changes. 
Studies have suggested functional differences between neuronal and  non-neuronal cells 
lines (109). Therefore we decided to perform the analyses in the Neuro-2A (N2a) 
neuroblastoma cell line derived from mouse to determine if a neuronal cell provided a 
better model system.  
Multiple PATs Enhance DAT Palmitoylation and Expression in the N2a Cells  
 Because we already determined a specific subset of DHHC enzymes the drive 
DAT palmitoylation in the LLCPK1 cells, we chose to evaluate a limited number of 
DHHC enzymes in the N2a cells, to determine if the previous results followed a similar 
pattern. To test this, N2a cells were transiently transfected with WT rDAT and/or select 
DHHC enzymes for 18 h and analyzed by ABE (Figure 16). In these experiments we 
found significant increases in DAT palmitoylation relative to control with the over-
expression of DHHC2 (147.3 ± 19%, p<0.05), DHHC3 (173.1 ± 6%, p<0.01), and 
DHHC8 (145.7 ± 26%, p<0.05), whereas DHHC5 (98.1 ± 1%) and DHHA2 (97.9 ± 2%) 
had no effect (p>0.05) on DAT palmitoylation, parallel to our findings the LLCPK1 cells.  
Additional experiments were performed to determine if the N2a cells also showed 













Figure 17: DAT palmitoylation increases total DAT expression in N2a cells. N2a cells were 
transiently transfected with WT rDAT and indicated HA-tagged DHHC coding plasmids 
for 18 h and assessed for total DAT expression. Equal amounts of protein were 
immunoblotted for DAT (representative blot shown) and band density was quantified and 
expressed as a fraction of control values normalized to 100% (means ± S.E. of 2-6 
independent experiments performed in duplicate). * P<0.05, ** P<0.01, *** P<0.001 




Figure 18: DAT palmitoylation increases transport Vmax in N2a cells. (A) N2a cells were 
transiently transfected with WT rDAT and the indicated HA-tagged DHHC coding 
plasmids followed by [3H]DA uptake.  Transport values obtained with co expression of 
DHHC enzymes were normalized to total protein. Values shown are mean ± S.E. of 3-5 
independent experiments performed in triplicate relative to controls normalized to 100%. 
*p < 0.05, ** p < 0.01 versus WT (one-way ANOVA with Dunnett’s Post hoc test). (B) 
DA transport saturation analysis of N2a cells co expressed with rDAT and DHHC2. Results 





cells were transiently transfected with WT rDAT and/or select DHHC enzymes for 18 h, 
cell lysates were subjected to SDS-PAGE, and immunoblotted for total DAT levels. Our 
results were similar to our previous findings, indicating that total DAT expression is 
enhanced when DAT is co-expressed with DHHC enzymes that increased DAT 
palmitoylation (Figure 17). DAT expression was significantly increased with the co-
expression of DHHC2 (131.2 ± 7%, p<0.01); DHHC3 (138.6 ± 13%, p<0.001); DHHC8 
(143.6 ± 15%, p<0.05); DHHC15 (151.5 ± 6%, p<0.05), DHH17 (139.0 ± 5%, p<0.01) 
whereas DHHC11 and the inactive DHHA2 enzyme had no effect on total expression 
(p>0.05). These results support our findings in the LLCPK1 cells, suggesting DAT 
palmitoylation oppresses DAT degradation.  
Palmitoylation Increases Transporter Capacity via an Alternation of DAT Transport 
Kinetics 
 Previous research has shown inhibition of DAT palmitoylation with 2BP results 
in a significant decrease in transport capacity (149). Therefore we wanted to investigate 
the functional effects of DAT palmitoylation when driven by the overexpression of 
DHHC enzymes. To do this, N2a cells were transiently transfected with WT rDAT and 
individual DHHC enzymes for 18 h, then assessed for [3H]DA uptake activity (Figure 
18A). We found that DA transport activity was significantly enhanced by all DHHC 
enzymes that increased DAT palmitoylation (DHHC2 130 ± 9%, p<0.01; DHHC3 145 ± 
8%, p<0.01; DHHC8 152 ± 21%, p<0.001; DHHC15 138 ± 5%, p<0.05; and DHHC17 
136 ± 10% p<0.05) but that uptake was not changed with the co-expression of DHHC 
enzymes that did not enhance DAT palmitoylation (DHHC11 107 ± 3% and DHHA2 98 
± 3%, p>0.05). To determine the mechanism underlying increased uptake activity, we 













Figure 19: Palmitoylation of DAT does not increase surface expression. N2a cells were 
transiently transfected with WT rDAT and the indicated HA-tagged DHHC coding 
plasmids followed by surface biotinylation analysis. Image represents eluted biotinylated 
fraction (upper panel) normalized to transferrin receptor (TrF) (lower panel). The 
histogram represents mean ± S.E of 5-8 independent experiments relative to controls 
normalized to 100%. p > 0.05 by ANOVA with Dunnett’s post hoc test. 
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affected by the overexpression of DHHC2 (Figure 18B). Saturation analysis showed 
DHHC2-induced increases in transport occurred via an increase in Vmax relative to 
control (9.20 ± 0.75 versus 5. ± 0.73 pmol/min/mg, p<0.05), with no effect on Km (1.02 ± 
.42 and 2.3 ± 1.40 nM, p>0.05). Together, these results indicate that DAT palmitoylation 
affects the transport capacity of the transporter. 
To investigate the mechanism of DHHC-induced DA transport increases, we 
analyzed surface expression of DAT. To do this, N2a cells were transiently transfected 
with WT rDAT and individually with DHHC2 and DHHA2 followed by analysis by cell 
surface biotinylation (Figure 19). In five independent experiments performed in 
duplicate, quantification of surface DAT normalized to the transferrin receptor for each 
condition showed surface levels of DAT were not different from control levels (DHHC2 
98 ± 7% DHHA2 104 ± 10% compared to control set at 100%, p>0.05), indicating that 
DAT surface expression is not affected by its palmitoylation status. Together with our 
[3H]DA uptake data, our results indicate that DAT palmitoylation increases transport 
Vmax via an alternation of surface transport kinetic capacity.  
Palmitoylation is Present on Surface Transporters 
Kinetic regulation of DA transport activity by palmitoylation requires the modification to 
be present on surface transporters. To examine this, rDAT LLCPK1 cells were subjected 
to subcellular fractionation following analysis by ABE of DAT palmitoylation (Figure 
20). Post-nuclear supernatants were subjected to differential centrifugation to generate 
fractions enriched in plasma membranes (16,000 x g pellets) or endosomes (200,000 x g 











Figure 20: Subcellular localization of palmitoylated DATs. rDAT LLCPK1 cells were 
homogenized and post-nuclear supernatants (totals) were subjected to differential 
centrifugation to produce 16,000 x g membranes and 200,000 x g membranes. Fractions 
were immunoblotted for Na+-K+-ATPase, Rab5A, or DAT. Samples were subjected to 
ABE for detection of DAT palmitoylation.  Results are representative of 3-4 independent 
experiments performed in duplicate. 
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Na+/K+-ATPase in the 16,000 x g membranes and the early endosomal marker Rab5A in 
the 200,000 x g membranes, confirming the separation. ABE analysis showed that 
palmitoylated transporters were mostly present in the 16,000 x g membranes, with a 
small amount present in the endosomal fraction. These results support the presence of 
palmitoylated DATs on the plasma membrane.  
DAT Palmitoylation at Cys580 
We next investigated Cys580, the major site of DAT palmitoylation, and the role 
this site plays in DHHC-induced DAT palmitoylation. To do this, LLCPK1 rDAT cells 
stably expressing the C→A mutation at 580 were transiently transfected with DHHC2 for 
18 h followed by analysis of palmitoylation by ABE (Figure 21A). In contrast to WT co-
expression of DHHC2 and C580A rDAT resulted in no change in DAT palmitoylation 
(DHHC2 87.7% ± 6% relative to control p>0.05). Transport activity of Cys580 and co-
expression of DHHC2 were also assessed (Figure 21B). In three independent 
experiments, DA transport activity was significantly increased with the co-expression of 
DHHC2 in WT expressing cells (p<0.05). Whereas co-expression of DHHC2 in C580A 
expressing cells resulted in no effect on DA transport activity (DHHC2/C580A relative to 
control 74 ± 10% p>0.05), indicating Cy580 is required for DHHC2-induced uptake. 
Taken together, these results indicate that Cys580 mediates DHHC2-induced DAT 
palmitoylation and increased DA uptake activity.  
 Previous studies have shown that DA transport Vmax is significantly reduced by 
conditions that inhibit DAT palmitoylation (149), suggesting that palmitoylation of 
Cys580 increased transport. To further investigate the role of palmitoylation on transport  
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Figure 21: Cys580 mediates DHHC2-induced DAT palmitoylation and effects on 
kinetics. (A) C580A rDAT LLCPK1 cells transiently transfected with DHHC2 were 
analyzed by ABE for DAT palmitoylation. Upper panels show representative results for 
ABE. Histogram shows quantification of palmitoylated DAT normalized for total DAT 
protein (means ± S.E. of 4 experiments performed in triplicate relative to controls 
normalized to 100%). p>0.05, relative to control by (Student’s t test). (B) [3H]DA uptake 
analysis in N2a cells transiently co-transfected with WT or C580A rDAT, and HA-tagged 
DHHC2 coding plasmid. Transport activity was normalized to total protein. Values 
shown are mean ± S.E. of 3-5 independent experiments relative to controls and C580A 




Figure 22: Cys580 modulates DA transport Vmax. LLCPK1 cells expressing WT and C580A 
were analyzed in parallel for [3H] DA saturation transport kinetics, total DAT expression, 
and DAT cell surface expression. (A) Representative immunoblots showing equal amounts 
of protein analyzed for DAT total and surface levels. (B) [3H] DA saturation analysis 
normalized for relative transporter surface levels. Uptake values shown are the mean ± S.E. 
of five independent experiments. (C) The histogram shows Vmax values for WT and C580A. 




kinetics we performed [3H]DA saturation transport analyses for C580A and WT DATs 
(Figure 22). All experiments were performed in parallel and include analysis of samples 
for total and surface DAT expression. Relative to the WT transporters values set at 100%, 
total and surface expression of C580A rDAT was 55 ± 5% and 56 ± 4%, respectively 
(Figure 22A). Figure 22B shows uptake saturation values for WT and C580A normalized 
for surface expression. The Vmax of C580A (397 ± 34 pmol/min/mg) was significantly 
less than the WT protein (697 ± 56 pmol/min/mg; p<0.05) (Figure 22C). Km values were 
not significantly different (WT 2.3 ± 0.8 µM, C580A 1.5 ± 0.6 µM; p>0.05). Similar total 
and surface expression levels of C580 DAT indicate alterations in transport are not due to 
differences in trafficking to the surface. 
Lateral Membrane Mobility of DAT 
We next wanted to investigate the lateral membrane mobility of DAT to better 
understand the function of DAT palmitoylation. To do this we co-expressed EYFP-DAT 
and select DHHC enzymes transiently in the N2a cells and analyzed lateral membrane 
mobility using FRAP (Figure 23). We assayed the lateral mobility of DAT using a 
circular bleach spot with the average diameter of 3 µm. The bleaching was performed at 
the edge of the membrane, photobleaching approximately 50-70% of the fluorescence 
signal. Representative images are shown in Figure 23A for DAT and DAT co-expressed 
with DHHC2.  The circles highlight the region of photobleaching and the subsequently 
recovery recorded over a 5 min period. Our results show, that co-expression with 
DHHC2, significantly increases the time of recovery as demonstrated by the recovery 
curves and the histogram (Figure 23B and C) (DHHC2 107.3 ± 17 sec vs control 30.4 ± 6 




Figure 23: Palmitoylation decreases membrane lateral mobility of DAT. N2a cells 
transiently transfected with EYFP-rDAT and indicated HA-tagged DHHC coding plasmids 
were assessed for lateral membrane mobility by FRAP. (A) Representative confocal 
images showing EYFP-DAT fluorescence concentrated on the plasma membrane at pre-
bleach, bleached, and recovery stages. (B) Fluorescence recovery curves for EYFP DAT 
expressed in N2a cells. Recovery was measure by normalized fluorescence intensity as a 
function of time (sec). (C) Time of recovery calculated based on FRAP experiments (means 
± S.E. of 3-5 independent experiments relative to controls) Total number of cells evaluated 
- control: 35, DHHC2: 25, DHHC11: 28 and DHHA2: 20. **p < 0.01, *** p < 0.001 versus 
control (one-way ANOVA with Dunnett’s Post hoc test).  
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recovery times similar to control (DHHC11 43.0 ± 5 sec and DHHA 40.6 ± 5 sec, 
p>0.05) (Figure 23B and C). Together these results indicated DAT palmitoylation 
decreases the lateral membrane mobility.   
Action of Psychostimulants on DAT palmitoylation 
DAT is the target for power addictive psychostimulants, therefore we wanted to 
investigate the effects of psychostimulants on DAT palmitoylation. To examine DAT 
palmitoylation, cells were pretreated with COC or METH for 30 min, washed extensively 
to remove extracellular drug, and assayed for DAT palmitoylation by ABE (Figure 24A). 
In three independent experiments, COC treatment resulted in no change in palmitoylation 
compared with untreated controls (94.8 ± 6%, p>0.05), whereas treatment with METH 
significantly reduced DAT palmitoylation (84.2 ± 4%, p<0.05). Time course studies 
showed decreased DAT palmitoylation at 30 min (83.3 ± 8%, p<0.05) and 60 min (82.1 ± 
4%, p<0.05) relative to basal (Figure 24B). 
To further examine the effect of psychostimulants on DAT palmitoylation, in vivo 
METH studies were performed in male Sprague Dawley rats (Figure 25A). In these 
studies, the animals were subcutaneously (SC) injected with COC (15mg/kg), METH 
(15mg/kg) or saline control for 30 min. This dose of drug produces detectable locomotor 
activity (159).  Animals were then decapitated, the striatum was isolated, and membranes 
were prepared, followed by analysis by ABE. In three independent experiments, COC 
treatment showed no change in DAT palmitoylation compared with saline controls (94.8 
± 6%, p>0.05) whereas METH treatment significantly reduced DAT palmitoylation 
(p<0.05). Time course studies animals were treated with METH (15mg/kg) for 10 min, 
30 min, and 60 min post SC injection (Figure 25B). We observed treatment with METH 
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significantly decreased DAT palmitoylation in as little as 10 min (66.8 ± 10%, p<0.01,), 
and continued for 30 min (50.8 ± 1%, p<0.001), and 60 min (47.9 ± 0.3%, p<0.01). These 
results are consistent with our previous results which indicated a differential response of 
psychostimulant substrates versus blockers in both heterologous cells and animals (75, 
152). Furthermore, these results indicate DAT palmitoylation is regulated by METH and 
not COC, which might be important for the clearance of DA in the synapse.  
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Figure 24: Regulation of DAT palmitoylation by psychostimulants in heterologous cells. 
LLCPK1 cells were treated with (A) 10 µM METH or 100 µM cocaine for 30 min at 37 ºC 
followed by assessment by ABE. Histogram represents quantification of palmitoylated 
DAT normalized for total DAT protein expressed as a fraction of basal values normalized 
to 100% (means ± S.E. of 4 experiments performed in duplicate). * P< 0.05, relative to 
control by (one-way ANOVA with Dunnett’s Post hoc test).(B)10 µM methamphetamine 
(METH) for 30 or 60 min at 37 ºC, cell membranes made, followed by assessment of DAT 
palmitoylation by ABE. Upper panels show representative ABE blots with matching total 
DAT immunoblots. Histogram represents quantification of palmitoylated DAT normalized 
for total DAT protein expressed as a fraction of basal values normalized to 100% (means 
± S.E. of 7 experiments performed in duplicate). * P< 0.05, relative to control by (one-way 
ANOVA with Dunnett’s Post hoc test). 
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Figure 25: Regulation of DAT palmitoylation by psychostimulants in vivo. Male Sprague 
Dawley rats were SC injected with (A) METH (15 mg/kg), cocaine (COC) (15 mg/kg), or 
saline control for 30 min. The animals were decapitated and striatal membranes were made 
following analysis for DAT palmitoylation by ABE. Upper panels show representative 
ABE blots with matching total DAT immunoblots. Histogram represents quantification of 
palmitoylated DAT normalized for total DAT protein expressed as a fraction of saline 
control values normalized to 100% (means ± S.E. of 3 experiments performed in triplicate). 
* p<0.05 (one-way ANOVA with Dunnett’s Post hoc test). (B) METH (15 mg/kg) or saline 
control for indicated time points. The animals were decapitated and striatal membranes 
were made following analysis for DAT palmitoylation by ABE. Upper panels show 
representative ABE blots with matching total DAT immunoblots. Histogram represents 
quantification of palmitoylated DAT normalized for total DAT protein expressed as a 
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Figure 25 continued: fraction of saline control values normalized to 100% (means ± S.E. 
of 2-3 experiments performed in triplicate). ** p<0.01, *** p<0.001 (one-way ANOVA 





Regulation of DAT Palmitoylation by DHHC Enzymes  
 Complex control of DAT is exerted by various regulatory processes, including 
palmitoylation. Protein palmitoylation increases protein hydrophobicity; mediates 
protein-lipid bilayers interactions; and can alter protein sorting, function, and regulation 
(112–116), however its role in DAT function is poorly understood. In this study, we have 
demonstrated for the first time that multiple DHHC enzymes drive DAT palmitoylation 
altering the function of the transporter. Figure 26 summarizes the numerous finding from 
my dissertation work and previous studies supporting DAT palmitoylation. In this model 
DAT palmitoylation is driven by a specific subset of DHHC enzymes resulting in 
enhanced DAT palmitoylation. Our findings reveal a connection between the increased 
DAT palmitoylation and total DAT expression. In all cases we observed enhanced total 
DAT expression when DAT palmitoylation was increased with the co-expression of 
DHHC enzymes, supporting an additional role for palmitoylation in opposing DAT 
degradation. We also found DAT palmitoylation increases transporter capacity with no 
change in surface expression, indicating changes in transport Vmax occur via a kinetic 
mechanism. With respect to membrane lateral mobility, we found DAT palmitoylation 
increases the time of recovery, suggesting palmitoylation decreases the membrane lateral 




Figure 26: Mechanism of DAT palmitoylation. A Schematic representation of DAT 
palmitoylation and depalmitoylation cycles. The red palmitate group represents a known 
site of palmitoylation on the C-terminus near the TM12/cytoplasm interface. Increased 
DAT palmitoylation catalyzed by select DHHC enzymes results in increased total DAT 
expression, increased DA transport capacity, and decreased lateral membrane mobility. In 
contrast depalmitoylation by PPT enzymes results in decreased palmitoylation, decreased 
transporter expression, decreased DA uptake capacity, and increase in lateral membrane 
mobility. Methamphetamine (METH), C580A mutant, and 2-bromopalmitate (2BP) all 




palmitoylation is regulated by METH in both native and model systems. Together these 
findings indicate that palmitoylation of DAT alters the function and regulation of the 
transporter.   
Our studies revealed that DAT palmitoylation can be catalyzed by several but not 
all, DHHC enzymes evaluated, suggesting a level of substrate specificity in both the 
LLCPK1 and N2a cells. Similar findings have been reported for other neuronal proteins 
(112, 125, 160, 161), suggesting that substrate palmitoylation by multiple DHHC 
enzymes is important for the mechanism of palmitoylation. The 23 DHHC enzymes are 
found present in many intracellular localizations including the Golgi apparatus, ER, and 
plasma membrane (133, 156), however it remains unknown where DAT is being 
palmitoylated at. From our results we can infer DAT is being palmitoylated in some 
degree in the Golgi since the immature form of DAT is palmitoylated; however, the 
multiple DHHC enzymes involved in DAT palmitoylation could suggest palmitoylation 
is taking place at multiple locations including the plasma membrane. The redundancy in 
substrate recognition might be important for the turnover of the protein, however remains 
unknown. The dynamic nature of palmitoylation and depalmitoylation could potentially 
allow for multiple palmitoylation/ depalmitoylation cycles to occur during the time DAT 
in synthesized to the time it is degraded. This process could require multiple DHHC 
enzymes to palmitoylate DAT at different subcellular locations effecting the overall 
function of the transporter.  
Further support for substrate specificity was validated by [3H]palmitate labeling 
and mutagenic studies, confirming DHHC2 significantly increases DAT palmitoylation. 
Our studies reveled that the enzymatic activity of DHHC2 is required for increased DAT 
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palmitoylation. Similar mutagenic studies have been reported (125, 130), supporting the 
idea that the intact DHHC motif is required for palmitoylation (138, 162). Studies have 
shown mutations of the Cys in the DHHC motif blocks both autoacylation and transfer 
activity of DHHC enzymes (126), however the exact Cys was unknown. Recently, it was 
discovered that the Cys of the DHHC motif is specifically required for the two step 
catalytic mechanisms of palmitoylation (140). Furthermore, the same study found 
mutation of the highly conserved cysteine rich domain outside of the DHHC motif also 
results in activity deficits (140), suggesting the importance of this region.  
Palmitoylation can alter membrane proteins in various ways, affecting the 
conformation and regulation (117–121). Therefore we investigated the functional effects 
of DAT palmitoylation. We found DAT palmitoylation significantly increased DA 
transport with no changes in surface expression, suggesting changes in DA transport are 
occurring via a kinetic mechanisms. Several observations support the occurrence of this 
type of transport. Down-regulation has been shown to still occur when ConA treatment is 
used to block PMA-induced DAT endocytosis (108). Furthermore, rat striatal 
synaptosomes prepared in hypertonic sucrose, which is known to inhibit clathrin-
mediated endocytosis (163), still resulted in down regulation when treated with PMA and 
2BP with surface levels unchanged (149). Our results further provide support that DA 
transport can undergo regulation at the plasma membrane via a kinetic mechanism.  
The mechanism for transport regulation by palmitoylation remains unknown, 
however it is most likely an indirect effect that is presumably affecting the rate of 
transport. Palmitoylation has been shown to affect many aspects of membrane proteins 
that could attribute to changes in transporter function (117–121). Specifically, 
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palmitoylation can affect the conformation of TMD (119, 164). Palmitoylation has been 
shown to facilities the re-orientation of TMDs, by maximizing hydrophobic matching and 
tilting a TMD peptide (117, 165). Evidence for this was provided by structural studies in 
artificial lipid membranes, which the addition of a palmitoylation chain induced the tilt of 
the helix in the membrane plane (165). More recently in vivo studies have suggested that 
this action also occurs in full-length proteins in biological membranes (117). These 
studies suggest the possibly that titling of TMD12 of DAT could affect the function of 
transporter, altering the transport mechanism. The substrate translocation pathways of 
DAT is formed by TMD1, TMD3, TMD6, and TMD8, (44, 55), while the major site of 
palmitoylation is found on TMD12, outside the inner core and does not contribute 
directly to the substrate active site. Substrate translocation occurs via an alternating 
access mechanism. DAT cycles through outward and inward facing conformations that 
allow for binding of substrates and release into the cytoplasm (21, 54). These 
conformations are controlled by extracellular and intracellular gates residues and the 
equilibrium between these conformations determines the rate of forward transport 
therefore a slight tilt of the TMD 12 could have major effects on transport activity. The 
dDAT structure revealed a latch-like C-terminal helix (Figure 27) thought to be important 
for interactions with the cytoplasmic face of the transporter. The C-terminal helix was 
found to interact with IL1 (Figure 27B), which interacts with TMD1a. The close 
proximal interaction with the cytoplasmic gate suggests the C-terminal helix may be 
important for activity and changes in palmitoylation could modulating transport (50). 
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Figure 27. C-terminal latch of the dopamine transporter. A. x-ray crystal structure of the 
Drosophila melanogaster dopamine transporter (dDAT).  (A). Locations of the open 
extracellular gate (red box), closed intracellular gate (blue box), and C-terminal latch 
(green box). (B). The C-terminal helix following TMD12 is bound to the cytoplasmic 
face of the transporter via ionic interactions with IL1. Polar and electrostatic bonds are 
represented by gray dashed lines. Image modified from A. Penmastal, K.H. Wang, and E. 
Gouaux. 2013. X-ray structure of the dopamine transporter in complex with tricyclic 




Palmitoylation can also alter protein-protein interactions (164). Alternations in 
protein interactions is thought to occur through either by steric hindrance, changes in 
conformation, and/or localization to the membrane interface (164). Palmitoylation has 
been shown to affect interactions of proteins in both positive and negative ways (119, 
164). Studies by McCormick et al. found palmitoylation is requires for the interaction of 
the mannose-6-phosphate receptor and a larger multiprotein complex important for 
lysosomal targeting (166), however others have shown palmitoylation hinders protein-
protein interactions (117, 167). DAT interacts with numerous proteins on both the N-and-
C-termini (77, 79, 86–91, 94) that affect the overall function of the transporter. Proteins 
like Rin, CaMKII, α-Syn, Park, and PICK1 all bind all on the C-terminus of DAT (79) 
and it is unknown if palmitoylation affects the interactions. Furthermore, the important 
FREKLAYA (residues 587-596) endocytic regulatory domain important for both basal 
and PKC-enhanced DAT internalization (87) is also near the C-terminus palmitoylation 
site. At this point it is unknown if DAT palmitoylation affects these important binding 
partners. It will be important in the future to determine if these interaction are effected in 
a positive or negative manner and if they are important for regulation of DAT.  
Additional validation studies were done to evaluate our palmitoylation deficient 
mutant, C580A for palmitoylation and activity when co-expressed with DHHC2. In these 
studies, we found DAT palmitoylation and transport activity was not increased when 
palmitoylation was driven by DHHC2, suggesting Cys580 mediates DHHC2-induced 
changes in DAT palmitoylation. As previously mentioned palmitoylation can alter 




Figure 28. Proposed mechanism of increased DAT expression by DHHC enzymes. 
Schematic representation of DAT palmitoylation, showing populations possessing 
decreased palmitoylation (left) or increased palmitoylation (right). Increased 
palmitoylation is driven by the overexpression of PAT enzymes, whereas depalmitoylation 
is catalyzed by PPT enzymes. Conditions that increase palmitoylation and total DAT 
expression are predicted to retain DAT in endosomes resulting in reduced lysosomal 
degradation. In contrast, decreased palmitoylation and total DAT expression is predicted 




However, our results indicate DHHC2 is increasing DAT palmitoylation and transport 
activity, by palmitoylating the transporter directly at Cys580.  
To further support increased DAT palmitoylation effects transporter function, we 
investigated total DAT expression. Our studies revealed that increased DAT palmitoylation 
results in increased total DAT expression, suggesting palmitoylation opposes DAT 
degradation. These results are consistent with our previous studies, which have shown that 
acute or chronic inhibition of palmitoylation by 2BP results in increased DAT degradation 
as detected by loss of full-length DAT and the appearance of DAT degradation fragments 
(149). We know that increased DAT expression is not found at the surface as demonstrated 
by the surface biotinylation experiments, suggesting increased expression is the result of 
decreased DAT degradation (Figure 28). We suggest that increased palmitoylation 
stabilizes DAT in the endosome and reduces DAT targeting to the lysosome, resulting in 
higher expression and reduced degradation. A small amount of palmitoylated DAT was 
found in the 200,000 x g fraction of the subcellular fractionation, indicating DAT is in fact 
in the endosomes. Multiple studies have shown that palmitoylation is important for 
regulating protein turnover (127). Increased protein turnover and reduced stability has also 
been found for palmitoylation defective mutants of multiple proteins including, vial 
membrane glycoprotein of Rous sarcoma virus, the Al adenosine receptor, and the 
chemokine receptor CCR5 (168–170). Furthermore, we found C580A DAT has a higher 
rate of turnover compared to the WT protein, suggesting palmitoylation stabilizes DAT 
(Amy Mortiz, University of North Dakota, personal communication). Our results provide 
additional support that palmitoylation opposes DAT degradation.  
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 Palmitoylation has also been shown to alter protein function by targeting 
palmitoylated proteins to lipid microdomains (164). It has been proposed that increased 
palmitoylation enhances the affinity of proteins for cholesterol-rich microdomains (164, 
171). The affinity of a protein for a lipid microdomain is dependent on multiple factors 
including: the amino acid composition of the TMD, the interaction of multiple TMD in 
homo-or hetero-multimers forms, and the interaction with protein binding partners that 
also have strong associates with lipids (164). Furthermore, it has been shown that 
disruption of cholesterol in microdomains with mβCD results in a significantly faster 
lateral diffusion of DAT in the plasma membrane (109). In addition, control experiments 
were performed in our lab in which the C580A palmitoylation deficient mutant and 
treatment with 2BP both resulted in decreased lateral membrane mobility (Madhur 
Shetty, University of North Dakota, personal communication). From our studies we 
speculate palmitoylation could be reducing the membrane lateral mobility of DAT in 
various ways. The obvious mechanism is palmitoylated DAT is targeted to lipid 
microdomains, thus reducing lateral membrane mobility and affecting the function of the 
transporter. However, recent data from our lab suggests reduced palmitoylation actually 
targets DAT to rafts domains (Madhur Shetty, University of North Dakota, personal 
communication), suggesting increased palmitoylation does not target DAT to lipid 
membrane rafts. Another mechanism which might result in reduced lateral mobility of 
DAT is protein-protein interactions. It is well known that DAT has multiple binding 
partners that affect its function (79) as previously mentioned. Furthermore, 
palmitoylation can promote protein-protein interactions by modifying the conformation 
of the protein (164). Therefore enhanced DAT palmitoylation could promote interactions 
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with known DAT binding partners, resulting in reduced lateral membrane mobility. DAT 
palmitoylation could also be promoting DAT oligomerization, again reducing lateral 
membrane mobility  
In this study we provided the first evidence that DAT palmitoylation is regulated 
by METH. We found treatment with METH for 30 and 60 min in LLCPK1 cells resulted 
in a significant decrease in DAT palmitoylation. In addition, animals SC injected with 
METH for 10, 30, and 60 min were also found to have decreased DAT palmitoylation, 
demonstrating an important similarity between native and model systems. Interestingly, 
cocaine treatment had no effect on DAT palmitoylation, suggesting a difference in 
regulation between the two drugs.  Similar studies have been done; however, 
phosphorylation was measured after METH treatment (39). In these studies, Cervinski et. 
al. found treatment with AMPH or METH resulted in a significant increase in DAT 
phosphorylation. The DAT blocker cocaine, however did not affect DAT phosphorylation 
but prevent the phosphorylation increase induced by METH (39). Together, these studies 
suggest palmitoylation and phosphorylation may be working opposite of each other in an 
unknown mechanism.  
Several observation support the occurrence of reciprocal regulation of DAT 
palmitoylation and phosphorylation after METH treatment. Most recently, our lab has 
demonstrated that the palmitoylation deficient mutant, C580A had enhanced basal DAT 
phosphorylation levels in comparison to WT (150). In reverse experiments, the 
phosphorylation mutant, S7A had increased DAT palmitoylation when assessed by [3H] 
palmitate labeling. Further pharmacological experiments were done and confirmed the 
mutagenic results. Additionally, regulation of DAT palmitoylation by DHHC enzymes 
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supports the reciprocity between DAT palmitoylation and phosphorylation. Studies have 
shown, treatment with METH, which increases DAT phosphorylation (39), results in 
DAT downregulation and endocytosis (39, 71–73). In contrast, our studies demonstrate 
enhanced palmitoylation by the over expression of DHHC enzymes drive DAT 
palmitoylation, resulting in increased DA transport capacity. Together these studies 
provide further evidence that palmitoylation and phosphorylation are reciprocally 
regulated and important for DAT regulation and function 
Similar mechanisms have been shown for other proteins as well (121, 172–174). 
Examples of this include the β2-adrenergic receptor in which palmitoylation of Cys341 
interferes with PKC-mediated phosphorylation of Ser345 and Ser346, modulating the  
capacity which the receptors interacts with Gs (172). Another example is 
phosphodiesterase 10A, in which phosphorylation of Thr16 regulates trafficking and 
localization by preventing palmitoylation of Cys11 (121). Although similar in 
mechanism, these examples are different from DAT because the phosphorylation and 
palmitoylation sites of β2-adrenergic receptor and phosphodiesterase 10A are in close 
proximity in the primary sequence, while DAT’s sites are far apart in the primary 
sequences. This could suggest that the N-and-C termini are in close proximity in the 
tertiary structure, however based on the current crystal structures, (44, 52) little is known 
about the N and C termini interactions.  
Disruption in dopaminergic signaling is thought to be the consequence of 
dysregulation of DAT resulting in abnormal DA clearance (175). Studies have shown 
non-coding single nucleotide polymorphisms and variable-number tandem repeats in the 
DAT1 gene to correlate with predisposition to various neurological and psychiatric 
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disorders (176). More recently, rare coding polymorphisms have been identified in 
patients diagnosed with ADHD ,bipolar disorder, and autism spectrum disorder (68, 177–
180). These mutations have been shown to affect DAT function in numerous way 
including elevated efflux and increased transporter phosphorylation (178–180).  
Likewise, we know from numerous studies that DHHC enzymes have been associated 
with dopaminergic and neuropsychiatric diseases such as schizophrenia, X-linked 
intellectual disability, Alzheimer disease, and Huntington disease (113, 141, 142, 146, 
147, 181, 182), highlighting the importance of this modification in proper neuronal 
function. Mutations in enzymes regulating palmitate removal can also result in disease 
(147, 148), indicating that palmitoylation is relevant to disease processes. Imbalances in 
DA in dopaminergic diseases may result from alterations in palmitoylation, therefore, 
DHHC enzymes that catalyze DAT palmitoylation could represent potential therapeutic 
targets for dopaminergic disorders and drug addiction. Overall, these results suggest that 
palmitoylation plays a critical role in promoting both short-and long-term regulation of 
DAT by controlling important functions of the transporter, thereby potentially impacting 









Figure 29: ABE analysis of increased DAT palmitoylation in the LLCPK1 cells. rDAT 
LLCPK1 cells transiently transfected with the indicated DHHC coding plasmids were 
harvested and membranes isolated, followed by assessment of DAT palmitoylation by 







Figure 30: ABE analysis of co-expressed DHHC enzymes that have no effect on DAT 
palmitoylation in the LLCPK1 cells. rDAT LLCPK1 cells transiently transfected with the 
indicated DHHC coding plasmids were harvested and membranes isolated, followed by 
assessment of DAT palmitoylation by ABE. Upper panels show representative ABE blots 
with matching total DAT immunoblots.
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ABE analysis in the N2a cells 
 
Figure 31: ABE analysis in the N2a cells. N2a- cells transiently transfected with the 
indicated DHHC coding plasmids were harvested and membranes isolated, followed by 
assessment of DAT palmitoylation by ABE. Upper panels show representative ABE blots 
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